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Abstract 
Smoking is a huge issue for social health and consequently there has been much research 
considering the relationship between tobacco use and many biological processes. One interesting 
field of study has identified epigenetic signatures of smoking using DNA methylation profiles. 
Up to this point, these studies were mostly carried out using the 450K BeadChip technology 
from Illumina. The new Infinium EPIC array is capable of quantifying DNA methylation at 
almost double the number of CpG sites and was used on whole blood from around 1200 
participants of Understanding Society. This allowed integration of the household study’s rich 
smoking-related data with DNA methylation levels spanning the entire genome using linear 
modelling. The R package limma was used for this and allowed the identification of novel, 
smoking-associated loci in this study that were differentially methylated between smokers and 
non-smokers. These regressions also revealed a decrease in the number, and thus significance, 
of probes differentially methylated with smoking in former smokers compared to current 
smokers, supporting the idea than these changes are reversed upon cessation. Additionally, this 
study showed that DNA methylation levels within smokers varied with increasing dosage 
whereby duration of tobacco use appears to be more important than intensity in driving changes 
to the methylome caused by smoking. Furthermore, this differential methylation was reversed 
once a person had quit smoking and the degree of this decay increased with cessation years. 
Taking these findings, it was then possible to create two quantifiable DNA methylation-based 
biomarkers of smoking capable of predicting both years spent smoking in current smokers and 
years since quitting in former smokers. This may then prove to be a useful tool in characterising 
disease risk given the number of differentially methylated loci located in important health-related 
genes, especially if DNA methylation is indeed related to their expression. 
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1. Introduction 
 
1.1. Smoking Epidemiology 
 
In 1964 the United States Surgeon General elucidated to the dangers of smoking in a landmark report (NIH, 
1964). Since then an overwhelming amount of evidence has led to the classification of smoking as the 
leading, preventable cause of morbidity and mortality worldwide and has been frequently linked to 
advanced aging and multiple cancers (Peto et al., 2000). The first link between smoking and lung cancer 
came from a group of German scientists in the late 1920's and led to the first anti-smoking campaign ever 
(Proctor, 1996). However, this was largely based on ideology rather than science and was discredited 
following World War 2 which may in part explain why many people continued smoking thereafter. In the 
present day, smoking is declining in most of the developed world however there are still an estimated 1.1 
billion tobacco users worldwide and this clearly presents a huge problem for public health (Doll et al, 2004). 
Therefore, an enormous amount of research has gone into the biology of tobacco smoking and ways to 
prevent its use. This work has revealed at least 98 chemicals found within tobacco smoke that are known 
to have specific toxic properties, with some directly leading to DNA damage and subsequently cancer 
(Kastan, 2008).  
 
Research into the genetics of smoking has disclosed a predisposition to nicotine dependence and this has 
now been firmly established (Ware et al., 2012). Nicotine exerts an overwhelming addictive effect on 
tobacco smokers but there is some variation in the extent of addiction between individuals. Twin studies 
have documented a heritability to nicotine dependence which gives some explanation to inter-individual 
differences in ability to quit smoking (Ingebrigtsen et al., 2011). Here, genetic variants can influence this 
risk where single nucleotide polymorphisms within genes coding for receptors and enzymes involved in 
neurotransmitter metabolism have been implicated through genome-wide association studies. The strongest 
associations came from a locus mapped to chromosome 15q24-                                                                                                                                                                                                                                                                                                                                                                                                                                            
25 that harbours a gene cluster coding for nicotinic acetylcholine receptor subunits. This is made up of 
CHRNA5-CHRNA3-CHRNB4, genes that mediate fast signal transmission at synapses (Hällfors et al., 
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2017). Moving on from this came gene-environment interaction studies, with the best example being the 
interaction of smoking with apolipoprotein E variants. The ε4 variant is a much poorer antioxidant than 
other variants and this reduced anti-oxidative resilience can lead to several diseases, namely cardiovascular 
disease, when in conjunction with the excessive oxidative stress of smoking (Stephens et al., 2003 and Isik 
et al., 2007). Recently a surge of interest in epigenetics has thus far focused on the epigenome’s response 
to pollutant, such as that found in cigarette smoke, and looked for signals common in all smokers. This 
differs to genetic research focusing on individual differences between smokers. The strongest signals here 
have involved the altered epigenetic modification to genes involved in the response to tobacco combustion 
products, such as AHRR. This was so robust in fact that measures of DNA methylation at such loci are able 
to distinguish between current, nascent and never smokers (Philibert et al., 2012). This also strengthens 
previous findings that smoke-less tobacco use was not associated with differential methylation at any sites 
in snuff users (Besingi et al., 2013). With this said, another finding suggested that even nicotine itself can 
alter the methylation levels of promotors in GABAergic neurons, those involved in the neurotransmission 
of GABA, whose principal role is to reduce neuronal excitability throughout the nervous system although 
the effects were fairly minor in comparison (Satta et al., 2008).  
 
The current understandings in smoking-related changes to the epigenome act to strengthen the link between 
genes and health-related phenotypes that is only possible through epigenetic research. Thus, using the 
wealth of smoking epidemiology study available, this project aims to build upon this and more specifically 
better comprehend how DNA methylation changes relate to smoking phenotype. Findings of this nature 
will allow the creation of a biomarker of smoking, a useful tool in disease risk management and prevention. 
Often self-reported data on smoking is unreliable and even accurate measures of environmental exposure 
can fail to fully account for the internal dose a person has been exposed to. Thus, using biological exposure 
measures can offer a much more sensitive and reliable biomarker that is more accurately related to the final 
health outcome of a smoker. 
 
1.2. DNA Methylation 
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Many biomarkers of tobacco smoke exposure have been utilized to characterize its biological effects and 
assess the subsequent impact on disease risk. One example is that of serum cotinine levels, an objective 
measure of nicotine exposure using a cutoff point of 14ng/mL but is one of many well-established 
biomarkers that fail to fully reveal the effects of past exposure. Epigenetic study however offers the 
potential for an early detection, sensitive and long term biomarker where measures of exposure, decades 
prior to the sample collection, can be observed (Zhang et al., 2016). This has enabled much better research 
into exposure induced risk of chronic diseases as it can reflect exposure to a variety of environmental factors 
linked to ill health and help in better understanding the underlying aberrant biology of smoking.  
 
Epigenetics is defined as heritable changes that can affect gene architecture and expression without altering 
the genetic sequence itself. The three pillars of epigenetic regulation are DNA methylation, histone 
modifications and non-coding RNA species. Modifications of these affect almost all nuclear processes, 
including gene transcription and silencing, DNA repair and replication and telomere function to name a 
few. DNA methylation is one such mechanism involving the addition of a methyl (CH3) group to DNA, 
often modifying the function of the genes at which it occurs (Lister et al., 2009). The addition of CH3 at a 
5-carbon of a cytosine ring, creating 5'-methylcytosine (5-mC), is the most widely characterized occurrence 
of any epigenetic mechanism. In mammalian DNA, this almost always occurs at 5'-CpG-3' dinucleotides, 
known as CpG sites. An exception of this occurs in embryonic stem cells where a lot of 5-mC is observed 
outside of CpG contexts (Ramsahoye et al., 2000). 
 
Within the human genome, CpG sites located inside of clusters, termed CpG islands, are mostly 
unmethylated whereas other CpG sites remain largely methylated. This acts to, at least in part, separatee 
the genome into transcriptionally active and inactive zones. CpG islands make up approximately 1-2% of 
the genome and around 50-60% of all genes contain a CpG island, encompassing gene promoters or exons 
most of the time. These are related to gene expression and when CpG islands in the promotor region 
becomes methylated, expression can be repressed. Noted exceptions to this include imprinted genes and 
those on the inactive X chromosome (Moore et al., 2012). Methyl groups are added to DNA by a family of 
enzymes called DNA methyltransferases (DNMTs) that catalyze the transfer of methyl groups from S-
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adenosylmethionine. DNMT1 is necessary to maintain already established DNA methylation patterns, 
whereas DNMT3a and DNMT3b seem to be required for the establishment of new or de novo DNA 
methylation patterns. Furthermore, deletion of any DNMT is lethal in murine and human cells, showing the 
indispensable functions methylation plays in mammals (Bestor et al., 2000).  
 
In conjunction with this comes DNA demethylation, the removal of the methyl group. This process is 
required for epigenetic reprogramming of genes and has been implicated in some disease mechanisms, such 
as tumor progression. It was previously thought that DNA demethylation only occurs passively through 
dilution of methylation marks via de novo DNA synthesis by DNMT1. Today it is known that methylation 
marks can in fact be actively erased through the direct removal of the methyl group, or through a 
combination of the two (Ohno et al., 2013). In mammals, direct excision of 5mC paired with G does not 
seem possible, so instead the methylated base undergoes sequential modifications that are converted by 
ten-eleven translocation enzyme-mediated oxidation. This family of 5-mC hydroxylases include TET1, 
TET2 and TET3 and may promote DNA demethylation by binding to CpG rich regions, preventing DNMT 
activity.  They work by producing 5-hydroxymethylcytosine (5-hmC) as the first intermediate and then 
further hydroxylating this intermediate to 5-formylcytosine (5-fC) and then 5-carboxylcytosine (5-caC). 
Thymine DNA glycosylase (TDG) can also directly excise 5-fC, allowing the subsequent base excision 
repair (BER) pathway to convert the modified cytosine back to its unmodified state (Bochtler et al., 2016).  
The biological significance of 5'-methylcytosine has been widely recognized and may reflect a global 
decrease of DNA methylation. This is likely a consequence of methyl-deficiency caused by a number of 
different environmental influences, including smoking, and quantification of global 5-mC could act as a 
molecular marker for disease (Robertson, 2005). Furthermore, a more recent study has shown small changes 
to levels of intermediate DNA methylation may be associated with complex disease phenotypes where 
these changes caused a cascade of events leading to altered glucocorticoid receptor (NR3C1) protein 
(Leenen et al., 2016). This is just two examples of a plethora of papers demonstrating not only the 
importance of DNA methylation but also how its role in disease phenotypes may be more far-reaching than 
previously thought. 
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1.3. Previous Findings 
 
The first discovery of a smoking-related DNA methylation marker came from Breitling et al (2011) and 
has since been followed by the identification of thousands of individual CpG sites with differential 
methylation between smokers and non-smokers. Smoking has also been linked to a small global decrease 
in DNA methylation as a whole (Ambatipudi et al., 2016). These sites span all 23 chromosomes of the 
human genome and have varying degrees of methylation changes when compared to those who have never 
smoked. The significance of the top hits is staggering and in terms of this and effect size, the mean 
difference in methylation values between smokers and non-smokers, the strongest signals are those located 
in AHRR and the 2q37.1 region. Furthermore, the large majority of significantly associated sites show 
reduced methylation levels in smokers. A notable exception to this are the strong positive effect sizes seen 
in MYO1G. This gene is a plasma membrane-associated class I myosin, abundant in T and B lymphocytes 
and mast cells and aids in cell elasticity. Thus, MYO1G could be associated with smoking-related fibrosis 
in several tissues (Olety et al., 2010). 
 
A large majority of smoking-related CpG sites are located within gene bodies. These were identified 
through epigenome-wide association studies (EWAS), and epidemiological studies have worked to further 
strengthen these findings and create biologically plausible associations with ill health. One way this has 
been done is by comparing DNA methylation at certain loci with disease phenotypes. A good example of 
this came with the discovery of the first smoking associated CpG site, cg0363183, located in the body of 
gene F2RL3, the coagulation factor II receptor-like 3 gene. The main function of this gene is to code for 
thrombin protease-activated receptor-4 (PAR-4). PAR-4 plays a role in platelet activation and cell signaling 
and is expressed in several tissues, including leukocytes and lung tissue. Thus, this could give some 
explanation as to why F2RL3 methylation is found to be related to risks of cardiovascular diseases (CVD), 
lung cancer and even mortality (Zhang et al., 2015) although DNA methylation’s role in this is still not well 
characterized. Perhaps stronger and more consistent associations have been made to CpG sites located in 
the genetic region of the aryl hydrocarbon receptor repressor (AHRR). This gene has been established as a 
possible tumor suppressor and it is suggested that smoking may affect the aryl hydrocarbon receptor when 
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tobacco smoking triggers the generation of polycyclic aromatic hydrocarbon (PAHs). These toxic 
chemicals can exert their effect through the aryl hydrocarbon receptor (AhR) and its binding partner, called 
aryl hydrocarbon receptor nuclear translocator (ARNT). AHRR competes with ARNT for binding to the 
AhR and can repress signal transduction. This then gives meaning to alterations in the methylation status 
and consequentially expression of the AHRR gene, suggesting its role as a mediator of PAH detoxification. 
Thus, AHRR may be involved in the metabolism of endogenous toxins found in cigarette smoke (Evans et 
al., 2008). 
 
Other identified probes were in fact not located in the transcriptional regions of a gene and instead observed 
in other locations in the genome which may not directly impact the coding sequence of the gene. DNA 
methylation at these loci is often more tightly linked to transcriptional silencing than elements further 
downstream, whose methylation does not always impact the magnitude of gene expression (Brenet et al., 
2011). Two examples of such sites, known to be associated with smoking, are cg19859270, located in the 
1st exon of G-protein coupled receptor 15 (GPR15) and several in the intergenic region of 2q37.1. The loci 
on chromosome 2q37.1 are adjacent to an alkaline phosphatase gene cluster. One of these genes, ALPPL2, 
is responsible for dephosphorylation of many proteins and nucleotides and is beneficial as a biomarker for 
many cancers, having already been well established as a tumor marker in ovarian and testicular cancers and 
seminoma (Albrecht et al., 2004). However, this is only reliable in non-smokers as ALPPL2 enzyme serum 
concentrations have been found to increase up to tenfold in cigarette smokers (Schmoll et al., 2004) but 
nevertheless this still hints at an underlying mechanism by which DNA methylation changes increase 
smokers risk to cancer. Additionally, smoking associations of GPR15 sites were first reported in a study by 
Wan et al. (2012), with suggestions about its correlation with current and long-term smoking. Afterwards, 
Tsaprouni et al. (2014) also showed that this gene was the only gene at the time that showed a clear trend 
of increased gene expression in smokers compared to non-smokers, and a negative correlation between 
gene expression and DNA methylation. This study then assumed that the decrease in DNA methylation at 
cg19859270 within GPR15 seen in smokers would likely lead to an increase in transcription. This finding 
was confirmed in two papers, published by Bauer et al. (2015) and Koks et al. (2015). This gene regulates 
T-cell migration and immunity and thus might explain its role in chronic inflammatory diseases and as a 
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HIV co-receptor. Further to this, GPR15 was also reported in interactions with ethnicity-dependent 
differentially prevalence of HIV, namely HIV2 in African Americans (Dogan et al., 2015), raising the 
possibility that, for certain loci, differential methylation could reflect a shift in blood cell mixture.  
 
Other strong signals have also been seen in the 5’ untranslated regions (5’UTR) of the PRSS23 and RARA 
genes, although their biological role in smoking has not thus far been well characterized. 5’UTRs are cis-
regulatory elements required to regulate translation. PRSS23 codes for serine protease 23 and is a member 
of the trypsin family. Trypsin is formed when the proenzyme form of trypsinogen, produced by the 
pancreas, is activated thus proposing a role for these enzymes in smoker phenotypes when differentially 
methylated and also their impact in pancreatitis of which smoking is a risk factor (Lankisch et al., 2015). 
RARA codes for retinoic acid receptor alpha. This is a nuclear receptor that transduces retinoid signaling 
alongside the retinoid X receptor (RXR) forming RXR/RAR heterodimers. In the absence of ligand these 
heterodimers repress transcription by recruiting co-repressors. If ligand binds to the complex, a 
conformational change is induced that allows recruitment of histone acetyltransferase co-activators. This 
rearrangement of the RARA gene is a feature of acute promyelocytic leukemia (Vitoux et al., 2007). 
 
Clearly a huge range of sites have been implicated in smoking-induced DNA methylation change, all with 
varying functions and importance in disease. As suggested in the studies mentioned, the genetic context of 
individually differentially methylated sites can help better understand pathophysiological processes that are 
activated or suppressed by changes in DNA methylation caused by smoking (Breitling et al., 2011). 
Consequently, such sites may contribute to a greater comprehension of smoking exposure by expounding 
smoking-related DNA methylation signatures or even help build a picture of an epigenetic mechanism that 
may lead to smoking-induced disease. In fact many of the mentioned sites have already been used in the 
construction of a reliable quantitative approach, with high specificity, for differentiating between the 
smoking status of individuals and this has been validated. One study created a predictor model of smoking 
exposure using bisulphite pyrosequencing of just four genomic loci that were differentially methylated 
between smokers and non-smokers. Combining these sites into a DNA methylation index gave a strong and 
positive prediction for previous smoking with an area under the curve (AUC) of 0.83 (Shenker et al., 2013). 
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However, given the huge variation of duration, intensity and years of cessation within smokers and ex-
smokers, using sites identified through a simply comparison of smokers and non-smokers will not fully 
divulge the consequences of DNA methylation changes and this project aims to build a more comprehensive 
methylation signature that takes this into account.  
 
When looking at dosage effects, much of the research up to this point in time has concentrated on the impact 
of pack years of smoking on the degree of DNA methylation changes within smokers. Pack years are 
calculated by multiplying the number of packs (20 cigarettes) smoked per day by the number of years 
smoked, and has been used to quantify lifetime cumulative exposure. This approach has achieved success, 
with one study by Zhang et al. (2015) disclosing a relationship between pack years and AHRR methylation 
in both current and lifetime exposure to tobacco smoke and even in smoking related mortality outcomes. 
Another by Ambatipudi et al. (2016) found that DNA methylation values fell in four loci within IER3 with 
an increasing number of pack years. However, there is some skepticism about this pack year model and 
some discrepancy in lung cancer incidence for those with the same amount of pack years. Two individuals 
may both have smoked for 20 pack years but if one of these persons has been smoking 0.5 packs per day 
for 40 years, they would likely have a hugely different risk compared to another person smoking 20 packs 
a day for 1 year even though in theory they have the same cumulative lifetime exposure. With this said, it 
would be better to include duration and intensity of smoking separately in any analyses looking into dosage 
effect (Peto et al., 2012). By doing so, some studies have found that intensity of smoking may be less 
proportional to incidences of smoking related disease than duration of smoking alone and genes 
differentially methylated in current smokers relative to never smokers are often significantly associated 
with duration of smoking as well (Ambatipudi et al., 2016). This suggests there may be more fundamental 
parameters, for instance age of onset or short periods of cessation, that should be taken into consideration 
to better characterize differential methylation and any successive health outcomes caused by tobacco use 
(Peto, 2012). One study supporting this theory found that an earlier age at smoking onset correlated with 
hypermethylation of RASSF1A which leads to a poor prognosis in primary non-small cell lung cancer (Kim 
et al., 2003). This all shows that further study of loci within other smoking related genes, and more complex 
modeling of smoking history is therefore necessary to explore precise dose response relationships with 
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DNA methylation and to give a more global understanding of smoking exposure in the hope to better 
understand the molecular mechanisms at play and this is another aim of this project.  
 
Figure 1.3.1. shows a comparison of effect sizes for the top 90 CpG loci reported in more than five studies 
from Joehanes et al. (2016), the largest analysis of epigenetic signatures of smoking to date. This paper 
made use of 16 independent cohort studies. This figure compares the average effect size between current 
and never smokers against former and never smokers and shows that a consistent pattern of differential 
methylation, in the same direction, is observed for former smokers as it was seen for current smokers 
although to a much smaller degree. In general, this suggests a reversibility of smoking-related changes to 
the epigenome upon smoking cessation. This finding was also confirmed in many other studies including 
those by Ambatipudi (2016), Guida (2015), Tsaprouni (2014) and Lee (2016) where they all demonstrated 
patterns of reversibility in DNA methylation level changes. Thus, this suggests that alterations in DNA 
methylation caused by active smoking are site specific, dynamic and reversible and this can be seen in the 
varying degrees of differences between current and former smoking DNA methylation values in Figure 
1.3.1. The clinical significance of smoking cessation has been well established and is known to reduce the 
increased risk smokers have of developing many diseases and cancers. It has been demonstrated that the 
ratio of lung cancer between current and former smokers increases sharply with time since quitting and it 
Figure	1.3.1.:	Effect	size	distributions	of	the	top	90	differentially	methylated	probes	from	Joehanes	et	al.	
(2016).Probes	are	ordered	in	relation	to	the		chromosome	it	is	located.	All	90	sites	were	identified	in	more	than	five	
studies,	from	Joehanes	et	al	(2016)	and	effect	size	here	is	a	measure	of	difference	in	Beta-values	between	smokers	
and	non-smokers	for	both	current	(red)	and	former	(green)	smokers.	
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is suggested that by stopping before middle age almost 90% of lung cancer risk attributed to tobacco use 
can be avoided later on in life (Peto et al., 2000). This effect remains even after adjusting for number of 
pack years (Vlaanderan et al., 2013). Furthermore, one paper showed an association of duration of smoking 
cessation with a significantly reduced risk of CIMP high colorectal cancer and suggested that quitting 
smoking induces a protective effect on the DNA methylation–related carcinogenesis pathway that leads to 
this cancer (Nishihara et al., 2013). However, the degree of this reduced risk may be over-estimated in 
many studies where risk is calculated by dividing the nearly constant smoker risk rate by the increasing 
non-smoker rate. When smoking ceases the rate of lung incidence does stops increasing steeply but still 
increases with age, much like most cancers where risk is often higher in older people (Peto et al., 2011). 
Some studies have also shown that it can take up to 20 years for some sites to reach full “methylation 
recovery” (Guida et al., 2015 and Zhang et al., 2014). Although demonstrating the reversibility of 
methylation marks is of great interest, it does not help explain what causes this site specificity, or the 
variation in DNA methylation. One aim of this project is to give a more in depth look into the decay of the 
DNA methylation signature. The hope is that this may garner a better idea of smoking induced methylome 
changes and the environmentally driven process that causes it. This, along with more complex dosage effect 
studies, may enable a quantification of smoking exposure that can better predict related disease risk.  
 
Although the pathological mechanisms underplaying many of these sites is poorly understood, they still 
pose benefits in their correlation with smoking exposure. In fact, there has been efforts made to use 
methylation at one CpG site, cg05575921 within AHRR, as a quantifiable biomarker for smoking cessation. 
Here this site was seen to be sensitive and specific to smoking status with a characteristic, receiver operated 
area under the curve (AUC) of 0.99 and this kind of study is ongoing (Philibert, 2015). A measurable 
increase in methylation at this site, taken at regular time points, could be used to help physicians accurately 
monitor time since quitting with the hope that this would encourage successful cessation of smoking 
(Philibert et al., 2016). 
 
Several studies have found other findings in their mining of smoking data that should be considered when 
studying variation in smoking-induced DNA methylation. Elliott (2014), Joehanes (2016), Lee (2016), 
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Zaghlool (2015) and Zhu (2016) all identified ethnic heterogeneity of smoking-related differential 
methylation patterns at several loci, such as cg05575921 in AHRR where differences in methylation were 
much higher in South Asian participants than those of a European origin. However, this may partly be down 
to generally higher statistically powered studies in European cohorts compared to other EWASs. Another 
study by Besingi et al (2013) investigated both tobacco and snuff smoking and showed that smokeless 
tobacco was not significantly involved in DNA methylation, indicating that the majority of epigenetic 
alterations may be caused by the burnt products of tobacco and not its basic components. Additionally, 
ppassive smoking may also impact DNA methylation. A recent paper has found that high levels (more than 
10 hours per week) of recent indoor second hand smoke exposure may be associated with lowered DNA 
methylation of AHRR in human monocytes, albeit with weaker associations than active smoking (Reynolds 
et al., 2016). All these factors will add to the differences in DNA methylation levels seen in smokers and 
thus can help produce a more reliable and highly applicable epigenetic signature of smoking. 
 
1.4. Understanding Society and EPIC Array 
 
This study will make use of a recently created genome-wide DNA methylation resource as part of the UK 
Household Longitudinal Study (UKHLS), Understanding Society. This has been funded primarily by the 
Economic and Social Research Council (ESRC). Understanding Society builds on the success of the British 
Household Panel Survey (BHPS) that was heavily used by researchers, generating hundreds of scientific 
publications. However, Understanding Society aims to support a wider range of research than BHPS and 
this DNA methylation resource aims to help in doing so (Buck and McFall, 2011). Longitudinal studies of 
this nature can provide understanding of the trajectories of individual life histories and this project focuses 
on the detailed recorded smoking information available from participant surveys. This comprised of sex, 
age, smoking status, number of cigarettes smoked per day, age when starting smoking and age when last 
smoked. The data used throughout this project was collected in the main survey in wave 3. Furthermore, 
upon blood collection, approximately 5 months after the main survey questionnaire, nurses also asked 
participants three more smoking-related questions which included if they had smoked within the past 30 
minutes, 24 hours and how many hours since last smoking. This will enable a more complex smoking 
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history to be elucidated that takes into account even short-term smoke exposure and is not limited to 
comparisons of smokers and non-smokers as is the case for many previous studies. Instead, models can be 
created that look into intensity, duration and years of smoking cessation and these factors alone could yield 
some interesting results that had not yet been fully established.  
 
Another huge benefit of Understanding Society comes with its longitudinal nature. The participants used 
in this study were also involved in the BHPS before joining with Understanding Society. Participants were 
visited once a year and thus complete data on the smoking status and number of cigarettes smoked by them 
is available for at least 9 consecutive years, from wave I through to R of BHPS, then followed by wave 2 
and 3 of Understanding Society. This allows a more precise smoking history to be deduced such as the 
differences in consistent, low smoking effects and those with lots of variation in the number of cigarettes 
smoked. Thus, Understanding Society will provide a great resource in the analysis of smoking and DNA 
methylation marks in this project.  
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2. Preprocessing and Modeling 
 
2.1. EPIC Methylation Array   
 
The participants used in this study were selected as they were part of BHPS before it was integrated into 
Understanding Society. This meant that the longest smoking histories prior to sample collection could be 
obtained and thus allowed the most comparisons to be made between this data and DNA methylation levels. 
To create this DNA methylation resource whole blood samples, taken from around 1200 participants in the 
wave 3 nurse visit of Understanding Society approximately 5 months after the main survey, were used. 
 
Most studies detailed thus far have made use of BeadChip technology in Illumina methylation arrays to 
quantify methylation at thousands of genomic loci at single-nucleotide resolution due to their low cost and 
high-throughput capabilities. These studies on smoking-associated DNA methylation have used the older 
450K array, however in this study methylome sequencing was carried out using the new Infinium 
Methylation EPIC BeadChip, with a coverage of over 850,000 CpG sites, almost double the size of its 
predecessor. These sites include over 90% of sites found in the 450K array and offer improved coverage of 
regulatory elements (Pidsley et al., 2016). The DNA from the samples was prepared, and the arrays 
processed, by Jon Mill’s laboratory at Exeter University using the protocol detailed by the manufacturer. 
The technology used in such microarrays first involves a bisulfite conversion of the genomic DNA to 
convert unmethylated cytosine to uracil which is then subjected to whole genome amplification (WGA) 
using hexamer priming and Phi29 DNA polymerase. The DNA is then enzymatically fragmented and 
purified primers, enzymes and dNTPs are then applied to a chip. This chip contains two bead types for each 
CpG locus and each bead type is attached to a single stranded 50-mer DNA oligonucleotide that differ in 
sequence at the free end, making them allele specific. One bead type corresponds to the methylated cytosine 
and the other to the unmethylated cytosine which after conversion to uracil is amplified as thymine in 
previous steps (Weisenberger et al., 2008). The fragmented DNA products are then denatured to single 
strands and hybridized to the chip via allele specific annealing to either the methylation specific probe or 
the non-methylation probe. This step is followed by single-base extension with hapten labeled 
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dideoxynucleotides where ddCTP is labeled with biotin and the others (ddATP, ddUTP and ddGTP) are 
labeled with 2,4-dinitrophenol (Steemers et al., 2006). At this point multi-layered immunohistochemical 
assays are performed by repeatedly staining with a combination of antibodies that differentiate between the 
two types. After, the chip is scanned to obtain intensities of the unmethylated and methylated bead types 
(Bibikova et al., 2011). The system further analyzes this microarray data to normalize the raw data and 
reduce experimental variation effects (Staaf et al., 2008). 
 
2.2. Pre-processing   
 
Pre-processing, quality control and normalization were carried out in the statistical environment of R (R 
Core Team, 2017). The bioconductor package bigmelon was used which has many methods for working 
with Illumina arrays. This package extends the capabilities outlined by Pidsley et al in the R package 
wateRmelon by adapting methods from the gdsfmt package for efficient memory use and management, 
overcoming the overheads associated with data handing in R (Gorrie-Stone et al., 2017).  
 
The entire dataset of 1187 samples was first normalized using the dasen function developed by Leonard 
Schalkwyk for the wateRmelon R package. This works by normalizing the methylated (M) and 
unmethylated (U) probe intensities. By doing so any technical variation can be more simply dealt with by 
adjusting these rather than the derived “raw” beta values which are the methylation level estimates 
calculated in the Illumina protocol with little normalization and adjustment. It also involves a combination 
of background adjustment of the M and U intensities and four separate, between-array quantile 
normalizations of methylated Type I, unmethylated Type I, methylated Type II and unmethylated Type II 
intensities (Pidsley et al., 2013).  To further elucidate any samples which are grossly affected by this 
process, the function qual, also by Schalkwyk, is used to assess the degree of which the normalized and 
raw beta values differ. It calculates and outputs the root mean square deviation, sum of squared differences 
(SSD), sum of absolute squared differences and root mean square error (RMSD) for each sample. A cutoff 
of >0.05 RMSD or >0.05 SSD was used as this appeared to allow good identification of samples which 
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were very obviously altered when normalised. Using this, 8 outliers were identified with large differences 
in their raw and normalized values, one of which had a drastically larger RMSD and SSD. 
 
After elucidating samples that had normalized badly, meaning those that showed discrepancies between the 
original and normalized intensities, the function outlyx was utilised to further compute data-outliers using 
a subset of probes from the large data set. This was developed by Tyler Gorrie-Stone for the wateRmelon 
package and first involves specifying the number of inter-quantile ranges to be discriminated from the upper 
and lower quantiles. This is identified from principal component analysis and in this case, was 2. These 
computed principal components are used to determine distance measures for each observation. Then, 
weights for location and scatter outliers are computed based on these distances and the combined weights 
are used to determine outliers (Filzmoser et al., 2008). In this case an arbitrary threshold of 0.15 for the 
final weight output was used meaning outliers were defined as samples with a combined weight of less than 
0.15. Here, 6 outliers were identified and these were also observed in the previous step using qual. These 
were thus removed from further analysis alongside the other two samples that had normalized poorly. 
 
The next step of quality control checked for sample quality with bscon, a function developed for 
wateRmelon by Louis El Khoury, Eilis Hannon and Leonard Schalkwyk. This function uses the green and 
red channel readings of the type I and type II bisulfite conversion data to return the median bisulfite 
conversion percentage value for each array. This quantity shows average conversion of unmethylated 
cytosine to uracil and is an important step in pre-processing the data as complete conversion is necessary 
for further study. It uses the intensities of sample-dependent controls included in the BeadChip to evaluate 
performance across arrays. Type I chemistry beta values are calculated by first dividing the first three 
control probes of the green channel and the second three control probes of the red channel by the sum of 
all six of these probes and the unconverted green channel probes (U4, U5, U6) and red channel probes (U4, 
U5, U6). Type II chemistry beta values are calculated by simply dividing the methylated red channels by 
the sum of methylated red and unmethylated green channels. This outputs a percentage value for bisulfite 
conversion. In general, most arrays achieved over 85% conversion however 4 samples had noticeably lower 
values than the rest of the data set and these were also removed from further analysis. It is important to note 
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here that updates to the EPIC array manifest removed control probes C6 and U6 but this thus far does not 
seem to hinder the function. 
 
Next, an R implantation of Horvath’s clock (Horvath, 2013), named agep, was used to predict the age of 
the samples. It forms a weighted average for measures of DNA methylation at 353 epigenetic markers on 
the human genome that were elucidated using an elastic net regression. This results in a linear regression 
model whose coefficients correspond to transformed age and this is used to predict “DNA methylation age” 
by plugging in the relevant beta values. Unfortunately, the Horvath clock was created using the older 450K 
microarray and thus 17 of the 353 CpG probe sites used in the DNA methylation-based age predictor are 
absent in the newer EPIC array but nevertheless prediction was still fairly accurate. However, one sample 
had a large age discrepancy of almost 30 years. Another quality check used was to visualize sex differences 
between samples. This was done by plotting principal component 1 against principal component 2 and 
showed that the sex of all participants was correctly matched. Finally, by plotting raw intensities per rack 
any obvious batch effects between the different plates are revealed. This showed some differences between 
plates and these also had varying methylation level (Beta-value) distributions suggesting some technical 
variation. It is then important to bear this in mind when carrying out downstream analyses and thus these 
have been counted for within the linear models, although normalization with dasen seems to correct for 
most of this variation.  Furthermore, one sample shows very low log2 methylated intensity and this was 
also identified in previous quality control steps and thus removed from further analysis. 
 
In total, 12 samples were removed from the dataset based on poor normalization and low bisulfite 
conversion during the making of the DNA methylation profile. This left a total of 1175 samples of good 
quality and that act normally when transformed. These were used in downstream analyses in conjunction 
with the smoking data. However, when creating smoking variables to be used in further analyses, 4 samples 
gave negative values for duration and a further 138 had incomplete smoking data and therefore these were 
also removed from the dataset to allow for the most comparative analyses. This left 1033 samples with 
reliable descriptive information to be used in linear models. When carrying these out, the ratio between the 
now quality checked methylated and unmethylated intensities were used to obtain an estimate of the 
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methylation level for each probe. This is calculated by dividing the methylated intensity with the sum of 
unmethylated and methylated intensity plus 100 (M/U+M+100). This is called a Beta-value where a value 
of 0 is equal to non-methylation, 1 equal to total methylation and a 0.5 value suggests one copy is 
methylated but not the other in the diploid human genome.  Logit transformed Beta-values, termed M-
values, have been used in the analyses outlined in this chapter. Beta-values have been shown to have high 
heteroscedasticity for sites that are highly methylated or unmethylated, meaning that the ability of a linear 
regression model to predict dependent variables are not consistent across all values of the dependent 
variable. Therefore, M-values are used throughout this project when elucidating differentially methylated 
probes and regions as these perform much better in terms of detection rate and true positive rate and their 
performance can be improved even further by applying a minimum threshold of difference whereas Beta-
values cannot (Du et al., 2010). Beta-values were only used when looking at effect sizes, which in this case 
constitutes the difference in average methylation between two groups. 
 
2.3. Linear Models 
 
Linear models were carried out in the statistical environment R, using the Bioconductor software package 
limma. This package allows differential methylation analysis of large-scale microarray data and the 
identification of differentially methylated CpG sites. Although originally created for gene expression 
analyses, it has proved to be a valuable tool for studying DNA methylation arrays of which the package’s 
linear modelling strategy works well and has been used by other studies (Ambatipudi et al, 2016). In this 
case, the package operates on a matrix of methylation values, the calculated and quality controlled M-
values, where rows represent a probe for each genomic feature, here these are CpG sites, and each column 
represents the participant sample. The limma function lmFit then fits a linear model to each row of data, 
taking into account a specified design matrix that details relevant information related to each sample array, 
and specifies the hypothesis to be tested. Within this study, the treatment-contrasts parametrization method 
was used to construct design matrices using the model.matrix function. This includes a coefficient for the 
comparison of interest itself rather than extracting the contrast after using a contrast matrix. Although the 
data is from two colour oligonucleotide arrays, linear modeling that compares DNA methylation between 
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two groups is effectively the same as analysis of variance (ANOVA) or multiple regression except that a 
model is fitted for every probe (Ritchie et al., 2015). 
 
For assessing differential methylation, limma uses an empirical Bayes method to moderate the standard 
errors of the estimated log-fold change and is implemented in the eBayes function.. This enables more 
stable inference and better statistically powered analysis. This is because the statistical methods 
implemented by the lmFit function can produce imprecise results when sample sizes are small but the data 
is of a high dimension, as with microarray data. Thus, the Empirical Bayes (EB) technique can offer gains 
in performance by leveraging information from the entire dataset, across the CpG sites in this case, when 
making assumptions about individual probes. EB in limma moderates genewise, or probe-wise, variance 
estimators by assuming a Bayesian hierarchical model for these variances and estimates the prior 
distribution from the marginal distribution of the inputted data itself rather than basing it on prior knowledge 
(Smyth et al., 2005, Phipson et al., 2016). The resulting fitted models, which have borrowed information 
across probes, were summarized using the topTable function to obtain a list of probes most likely to be 
differentially methylated between the groups specified in the design matrix. The resulting object also shows 
the p-values adjusted using the Benjamini-Hochberg method to control the expected false discovery rate 
(FDR) as well as the the corresponding log2-fold-change, average log2-expression for each probe over all 
arrays and channels and t and F statistics (Ritchie et al., 2015). The large majority of functions used in 
package were authored by Gordon Smyth.  
 
In short, limma allows the construction of both simple baseline and complex experimental design matrices 
where both categorical and continuous variables may be handled in much the same way and where all 
included variables can be studied at the same time. It also expands this using its empirical Bayes method to 
average variability of DNA methylation over all CpG sites used in the comparisons of interest leading to 
hopefully truer variances. This makes it an accessible, powerful R package for differential methylation 
analysis.  
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2.4. Kernel Smoothing 
 
To better understand the association of individual CpG sites found to be differentially methylated between 
smokers and non-smokers via limma, differentially methylation regions (DMRs) were identified using the 
Bioconductor package DMRcate. DMRs are stretches of DNA within the genome that involve a minimum 
of 2 adjacent sites or groups of sites in close proximity that have different methylation patterns between 
samples. DMRs are often of more value than single CpG sites that are not contextualized by the methylation 
status of neighbouring probes. DMRcate identifies these using kernel smoothing, a statistical method to 
estimate a function reflecting DMRs as the weighted average of neighbouring differential methylation 
signals identified using the same design matrices and corresponding M-values used within limma. These 
CpG sites are first annotated with their chromosome position and test statistic through the function 
cpg.annotate. This makes the method agnostic to other site annotations other than spatial ones and passes 
the square of the moderated t statistic, calculated for each EPIC probe to the next stage in the DMRcate 
protocol. To control for multiple testing an FDR cutoff of 0.05 was used to specify which CpG sites are 
individually significant, as done before. This is also used to index default thresholding in the following 
steps (Peters et al., 2015). The resulting object is then passed to dmrcate, the main function of the package, 
which compares two smoothed estimated per chromosome, one weighted with the test statistic and one not, 
for null comparison, to identify significantly differentially methylated regions. The recommended values 
for lambda, the number of nucleotides for the gaussian kernal bandwidth used in smoothed-function 
estimation, and C, the scaling factor for bandwidth, was used and set to 1000 and 2 respectively. This meant 
that half a kilobase represents 1 standard deviation of support which has been shown to hold near optimal 
prediction of sequencing-derived DMRs for 450K experiments. No empirical testing has yet been done for 
the best parameters when using EPIC array data and thus it is necessary to be cautious about results from 
this analysis or risk type I errors. Lambda here also informs the DMR bookend definition where gaps greater 
than or equal to lambda between significant CpG sites will be in separate DMRs. The Gaussian kernel is 
calculated where lambda over C is equal to sigma.  
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This approach then first applies standard linear modelling to the data and then applies gaussian smoothing 
to the resulting CpG sites test statistics using a given bandwidth. It then models these smoothed test statistics 
using the method outlined by Satterthwaite (Satterthwaite, 1946) and computes P values based on this 
model. These are then adjusted and a threshold employed, giving FDR-corrected significantly associated 
sites and those nearby each other are finally agglomerated using the specified bandwidth. The resulting 
DMRs were then obtained using the extractRanges function that takes the dmrcate output to create a 
GRanges object, annotating the DMRs to promotor overlaps using the specified reference genome hg19 
(Peters et al., 2015).  
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3. Qualitative Smoking 
 
To determine the differences in the DNA methylation of smokers, ex-smokers and non-smokers, whole 
blood was collected from participants of Understanding Society. Participants were then divided into three 
qualitative categories; never, former and current smokers, based on self-report data collected in the wave 3 
questionnaires. For the purpose of these analyses a sample of participants were taken from each category 
to create three equal sized groups of 175 each and the general characteristics of those who contributed this 
data are shown in Table 3.1. This was done to prevent spurious associations that might occur from differing 
sample sizes of the smoking strata.  At the time of blood collection, the 525 participants used were aged 
between 28 and 96, with a mean age of 57.04 ± 14.88. As the methylation profiles were carried out using 
whole blood, DNA methylation based estimates of the leukocyte subpopulations were calculated using the 
estimateCellCounts function from the minfi R package. This implements the reference-based algorithm 
created by Houseman and team (2012) using DNA methylation profiles from purified leukocyte samples 
by which the algorithm performs linear constrained projection (CP) to calculate the distribution of white 
blood cells within a sample. This showed that those who had quit smoking had lower proportions of CD8T 
cells and a higher proportion of monocytes than both current smokers and those who had never smoked. 
Smokers and former smokers also had slightly higher proportions of granulocytes and CD4T cells, and 
current 
Table	3.1.:	General	characteristics	of	participants	used	in	qualitative	smoking	analyses	
Characteristic All Never Former Current 
Sample size 525 175 175 175 
Sex (Male:Female) 228:297 68:107 95:80 65:110 
Age, years (Mean±SD) 57.04±14.88 56.79±13.98 62.37±15.56 51.95±13.20 
CD8T (Mean±SD) 0.073±0.041 0.075±0.045 0.067±0.038 0.079±0.039 
CD4T (Mean±SD) 0.123±0.059 0.119±0.054 0.123±0.064 0.126±0.059 
NK (Mean±SD) 0.040±0.037 0.047±0.042 0.046±0.037 0.028±0.030 
Bcell (Mean±SD) 0.052±0.027 0.051±0.025 0.051±0.029 0.054±0.026 
Mono (Mean±SD) 0.040±0.021 0.040±0.019 0.042±0.023 0.036±0.019 
Gran (Mean±SD) 0.686±0.084 0.682±0.080 0.685±0.089 0.691±0.081 
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smokers had much lower levels of natural killer cells than both never and former smokers. Given the effect 
smoking has on innate immunity, it makes sense to see such changes in white blood cell distributions 
(Mehta et al., 2008).  
 
3.1. Current vs Never Smokers 
 
To start considering the relationship between smoking and methylation within Understanding Society, a 
sample of 175 current smokers and 175 never smokers were first compared. To do so, linear regression 
analysis was used within the limma package in R to identify changes in DNA methylation levels between 
these two categories, coded as 0 for current smokers and 1 for never smokers. To regress out known 
confounders, age, sex, blood process day and counts for CD4+ and CD8+ T cells, natural killer cells, B 
cells, monocytes and granulocytes were included in the model. Furthermore, batch effects were observed 
between samples on different plates during pre-processing and thus this information was also included in 
the model although, as stated earlier, normalization of the data corrected for most of these differences. 
 
To control for type 1 errors, or “false positives”, the FDR-controlling procedure was used at a false 
discovery rate of 0.05 (Benjamini and Hochberg, 1995). All adjusted P-values below this point were 
deemed as significant and this revealed 5198 differentially methylated probes (DMPs) between current and 
never smokers. These consisted of 3058 hypomethylated and 2140 hypermethylated CpG sites spanning 
the whole genome at varying methylation states and degrees of difference. Of these, 3838 probes were 
annotated to 2640 genes found in the UCSC database, leaving 1360 unannotated sites contained within 
intergenic regions. The average effect size, or methylation difference, of each of these probes, along with 
their significance and chromosome location, are summarized in Figure 3.1.1.  A more stringent cutoff of 
Bonferroni 5% level (Dunn, 1961), which in this case with 866,895 genomic loci being tested and compared 
is 5.76 x 10-8, revealed 610 probes that were differentially methylated. The effect sizes seen in the DMPs 
between current and never smokers ranged from -0.256 to +0.154, with a huge surplus of negative over 
positive directions of change. This is in line with previous findings. These hypomethylated sites also tended 
to have the strongest significance values and largest effect sizes. Further still, looking at the average 
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methylation difference of all >850,000 probes, more than half were hypomethylated in smokers. A simple 
and interesting explanation of this could be the activation of a number of “clean up” systems to aid in the 
removal of harmful toxins found in cigarette smoke. If DNA methylation does indeed impact the gene 
expression and resulting protein products than hypomethylation of such genes would cause this activation. 
 
 
Over one quarter of the identified DMPs are located in non-coding regions of the genome which consist 
largely of repetitive DNA, including many tandem repeats such as mini- and microsatellites. These make 
up more than 50% of the genome and CpGs in these regions have been shown to remain mostly methylated. 
This includes transposable elements (TEs) that may change chromosome locations and alter the genetic 
identity of cells. TEs are often hypermethylated, silencing transcription of the TE-encoded enzymes needed 
for their transposition.  DNA methylation thus acts to protect the genome’s integrity and loss of DNA 
methylation at these regions thus may reactive transposable elements (Levin and Moran, 2011). Given that 
Figure	3.1.1.:	Summary	of	5198	significant	CpG	sites	differentially	methylated	between	current	and	never	
smokers	at	false	discovery	rate	P	<	0.05.	Red	line	indicates	Bonferroni	threshold.	Each	CpG	site	is	
represented	by	significance	as	shown	by	their	–log(P-value)	values	(y-axis)	and	effect	size	and	direction	(x-
axis),	the	mean	β	value	difference	between	groups.	Associations	are	colour-coded	in	reference	to	the	
chromosome	the	CpG	site	is	located	on.	
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DNA hypomethylation most commonly arises outside of promotors, in repetitive elements and peri-centric 
DNA, chromosomal rearrangements may play a large role in the aberrant nature of methylome changes and 
indeed that of smoking (Ehrlich, 2008). In fact, global genome-wide hypomethylation has also been seen 
to induce genome instability and is one of the earliest molecular abnormalities seen in cancer. It has also 
been described following carcinogen exposure and in cells with altered differentiation and proliferation 
states (Issa et al., 1999 and Lisanti et al., 2013). 
 
Cigarette smoke exposure itself is one of the most powerful modulators of DNA methylation and may aid 
in the understanding of DNA hypomethylation seen in smokers. Firstly, carcinogens found in cigarette 
smoke, such as arsenic and polycyclic aromatic hydrocarbons (PAHs) can lead to DNA damage and the 
recruitment of DNMT1 where CpG sites adjacent to repaired nucleotides become methylated (Cuozzo et 
al., 2007). Secondly, nicotine can affect gene expression when it binds to nicotinic acetylcholine receptors, 
activating cAMP response element-binding protein. This pathway has been shown to downregulate 
DNMT1 (Satta et al., 2008). Thirdly, smoking may indirectly impact DNA-binding factors which in turn 
prevent de novo methylation of CpG sites in these motifs (Han et al., 2001). Lastly, cigarette smoke is 
known to induce hypoxia where carbon monoxide binds to haemoglobin and decreases oxygenation of 
many tissues. This then caused HIP-1α-dependent upregulation of methionine denosyltransferase 2A, 
known to synthesis S-adenosylmethionine, the major methyl donor used for DNA methylation (Liu et al., 
2011). This together can help understand the cause of altered epigenetic landscapes found in smokers within 
this study and the large supply of hypomethylated sites. 
 
Hypomethylation of some genes also makes sense biologically, for example the strongest smoking-
associated CpG site cg05575921 is located in the AHRR gene on chromosome 2 which acts to detoxify 
toxins found in cigarette smoke. In this study a total of 39 DMPs were situated in this gene, including some 
novel probe associations from the EPIC array. These sites had FDR adjusted P-values ranging from 3.06 x 
10-102 to 4.18 x 10-2 and all were featured in the gene body, between the ATG and stop codon, with the 
exception of cg26954197 found in the 3’UTR of AHRR, between the stop codon and poly A signal. This 
has been well established in a number of papers (Shenker et al., 2013, Philibert et al., 2012). DNA 
		
25	
methylation in gene bodies has even been associated with altered DNA transcription and is common in 
ubiquitously expressed genes (Suzuki and Bird, 2008). Additionally, the effect size, a measure of mean 
difference in beta values between current and never smokers, ranged widely from -0.256 to 0.061. This 
suggests CpG sites within AHRR become both hypermethylated and hypomethylated and may be explained 
with context within the gene as the hypomethylated sites tended to be closer to CpG islands which are 
known to be unmethylated for the most part.  
 
 
The top ten hypomethylated and hypermethylated probes, all showing more than a 5% difference in DNA 
methylation between current and never smokers, are shown in Table 3.1.1. These include well known 
smoking-associated methylation differences in the AHRR, F2RL3 and RARA as well as those in the 
Table	3.1.1.:	Top	10	hypomethylated	and	hypermethylated	DMPs	associated	with	smoking	(current	vs	never	
smokers)	
Illumina	Probe	
ID	
Chr	
Number	
Chromosome	
position	(bp)	
Design	
Type	
UCSC	Gene	
Name	
UCSC	Gene	
Region	
Present	
in	450K	
Array	
FDR	
Adjusted	P	
Value	
Mean	
Effect	
Size	
Hypomethylated	in	current	smokers	
cg05575921	 5	 373378	 I	 AHRR	 Body	 TRUE	 3.06E-102	 -0.26		
cg21566642	 2	 233284661	 I	 	  TRUE	 1.24E-82	 -0.17		
cg01940273	 2	 233284934	 II	 	  TRUE	 3.89E-77	 -0.13		
cg03636183	 19	 17000585	 II	 F2RL3	 Body	 TRUE	 2.17E-55	 -0.13		
cg17739917	 17	 38477572	 II	 RARA	 5'UTR	 FALSE	 4.98E-52	 -0.10		
cg21161138	 5	 399360	 II	 AHRR	 Body	 TRUE	 3.22E-41	 -0.10		
cg14391737	 11	 86513429	 II	 PRSS23	 5'UTR;Body	 FALSE	 1.18E-39	 -0.09		
cg25648203	 5	 395444	 II	 AHRR	 Body	 TRUE	 7.07E-36	 -0.08		
cg18110140	 15	 75350380	 II	 	  FALSE	 6.96E-35	 -0.10		
cg22812571	 2	 233286229	 II	 	  FALSE	 1.03E-34	 -0.10		
Hypermethylated	in	current	smokers	
cg12803068	 7	 45002919	 II	 MYO1G	 Body	 TRUE	 8.92E-20	 0.11		
cg05009104	 7	 45002980	 II	 MYO1G	 Body	 FALSE	 2.82E-15	 0.06		
cg13039251	 5	 32018601	 II	 PDZD2	 Body	 TRUE	 2.53E-11	 0.06		
cg15542713	 1	 42385581	 II	 HIVEP3	 TSS1500	 TRUE	 8.29E-11	 0.06		
cg04414766	 3	 22412963	 II	 	  FALSE	 1.85E-10	 0.09		
cg24049493	 1	 42385941	 II	 HIVEP3	 TSS1500	 TRUE	 5.68E-10	 0.05		
cg22635676	 2	 241975971	 I	 SNED1	 Body	 TRUE	 1.12E-09	 0.15		
cg08035323	 2	 9843525	 II	 	  TRUE	 1.14E-09	 0.06		
cg26718213	 2	 241976080	 II	 SNED1	 Body	 TRUE	 1.49E-09	 0.08		
cg11207515	 7	 146904205	 II	 CNTNAP2	 Body	 TRUE	 1.54E-09	 0.05		
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intergenic region of 2q37.1. Here, both probes seen in studies using the older 450K array and new probes 
unique to the EPIC array were differentially methylated in these genes and thus their strong links with 
smoking has not only been replicated but strengthened by this study. The top 20 DMPs also included less 
reported genes such as the hypermethylation of CpG sites in HIVEP3, located on chromosome 1, but little 
is known about its role in smoking phenotypes. It is however a member of the human immunodeficiency 
virus type 1 enhancer-binding family of proteins and binds the recognition signal sequence for 
recombination of immunoglobulin and T-cell receptor gene segments (Mak et al., 1998) suggesting a role 
in immunity which is impacted by smoking. It is also of note that hypermethylated sites had much smaller 
significance values than the top hypomethylated loci despite their equally large effect sizes.  
 
The second most commonly observed annotated gene, second only to AHRR, was ZMIZ1. With 18 
smoking-related DMPs ranging in FDR adjusted P-values from 3.03 x 10-23 to 4.61 x 10-2 and effect sizes 
ranging between -0.042 and 0.061 it is definitely of interest. The association of ZMIZ1 with smoking has 
been previously identified (Besingi et al., 2013) and its encoded protein has been shown to regulate the 
activity of some transcription factors, including the androgen receptor (AR). ZMIZ1 interacts with the 
transactivation domain of AR and has been found to augment its transcriptional activity in human prostate 
cancer cells and moreover, it co-localizes with SUMO-1 to enhance sumoylation of AR. Thus, decreased 
methylation of ZMIZ1 may decrease AR-mediated transcription and lead to a number of downstream 
consequences (Sharma et al., 2003). One study found that smokers had a significantly higher mean number 
of CAG repeats within the AR gene and lower levels of testosterone than non-smokers. It also found that 
the sperm of those who smoke had lower motility and increased morphological defects (Mitra et al., 2012).  
 
ZMIZ1 is also a known diabetes susceptibility gene, a disease of which smoking is a risk factor, with 
suggestions that tobacco use may cause increased inflammation and even directly impact insulin resistance 
(Xie et al., 2009). Other DMPs were located in ANPEP, another gene linked to diabetes in which 
methylation was significantly associated with gene expression, suggesting that the four smoking DMPs 
located in this gene may then be linked to altered gene function. ANPEP codes for the alanine 
aminopeptidase enzyme, a membrane-associated peptidase involved in a broad range of cellular processes 
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which could be impacted by smoking (Ligthart et al., 2016). The presence of smoking-related DMPs in 
these two genes offers support for the increased risk of diabetes many smokers have and hints at the 
potential biological mechanisms effected in those with diabetes.  
 
Of the 5198 significant CpG sites associated with smoking at FDR < 0.05, 2780 were unique to the Illumina 
EPIC array. Given the increased coverage of this BeadChip, this offers huge potential for the identification 
of novel associations between smoking and DNA methylation changes. Within the annotated sites, this 
includes many genes that were not previously covered in the older 450K array. The novel gene with the 
largest number of DMPs was GNMT on chromosome 6, seen in 8 probes differentially methylated between 
current and never smokers. Probe targets to the GNMT gene ranged little in their significance, from 1.12 x 
10-4 to 4.73 x 10-2. Although these may not be as strongly linked with smoking as other sites, these probes 
were located in gene regions of particular interest. Most were seen within 200 bases upstream of the 
transcription start site (TSS) or just downstream within the 5’UTR of the first exon. As stated previously, 
DNA methylation of sites in these components may be more closely linked to the transcription of genes 
like GMNT than those further downstream and thus are more likely to impact gene expression. GMNT codes 
for an enzyme called glycine N-methyltransferase which acts to regulate the ratio of S-adenosylmethionine 
(SAM), the methyl donor for DNMTs, and S-adenosylhomocystein (SAH). It does so by competing with 
tRNA methyltransferases for SAM, increasing SAH levels which in turn acts as an inhibitor for tRNA 
methyltransferases, reducing methylation. Thus, GNMT is important for maintaining cellular homeostasis 
and deficiency of this enzyme has been linked to liver disease and hepatomegaly (Luka et al., 2009). All 8 
GNMT CpG sites became hypermethylated in smokers with relatively small effect sizes where differences 
in mean Beta-values between smokers and never smokers ranged from 0.009 to just 0.003. Hypomethylated 
GNMT could be linked to the aberrant and widespread hypomethylation seen in smokers which may be 
exaggerated if this gene became over expressed. Furthermore, GNMT has been suggested to detoxify 
environmental carcinogens such as polyaromatic by binding to these hydorcarbons and inhibiting the 
formation of DNA adducts (Yen et al., 2013) although this does not help explain why this is seen to be 
hypermethylated in smokers. However, given the difference in DNA methylation seen in smokers the 
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associations of GNMT with tobacco use make sense biologically and present a novel insight into the 
underlying mechanism causing such changes. 
 
Stronger novel associations were observed in probes cg00045592 (FDR 2.71 x 10-22) and cg04009575 (FDR 
7.56 x 10-6) which were not present in older microarrays by Illumina. These are located in CpG sites within 
the 5’UTR of the signalling lymphocytic activation molecule (SLAMF7) gene on chromosome 1. 
Expression levels of SLAMF7 have been shown to correlate with smoking behaviour (Charlesworth et al., 
2010) but its association with smoking-induced methylation changes has not been shown until now.  This 
gene is a receptor present on immune cells and is known to be expressed on multiple myeloma cells. This 
finding lead to the production of elotuzumab, an anti-SLAMF7 antibody used in its treatment and works 
by enhancing natural killer cell activation leading to cell cytotoxicity of myeloma cells. SLAMF7 also 
mediates both the inhibitory and activation effects on natural killer cells depending on the expression of its 
adaptor, sarcoma-associated transcript 2 (EAT-2). The association of this gene with smoking may then 
relate to the large amount of research on the consequences of cigarette smoke inhalation on inflammation 
and immune suppression (Guo et al., 2015 and Lee at al., 2012). Methylation change at SLAMF7 may then 
in part relate to the drastically lower proportions of natural killer cells observed in current smokers 
compared to both never and former smokers within this study and the impact this would have on their innate 
immune system. 
 
The genetic contexts of some novel probes identified in this study have already been previously reported 
in papers. These studies used the chromosomal coordinates of unannotated smoking DMPs, for instance 
those lying in within intergenic regions, to obtain their nearest corresponding gene symbol. However, given 
the wider coverage of the EPIC array compared to the previous 450K, confirmation of DNA methylation 
changes at some of these genes has been established in this study and strengthens their role in smoking-
induced epigenetic landscapes. One such gene is ELMSAN1 (Ambatipudi et al., 2016). This gene, located 
on chromosome 14, contained at least 6 of the identified smoking DMPs and codes for the ELM2 And 
Myb/SANT Domain Containing 1 protein. A histone deacetylase complex (HDAC) called the MiDAC 
complex was identified fairly recently and given its name, Mitotic Deacetylase Complex, after higher levels 
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of this complex were observed in cells arrested in mitosis. This complex contains histone deacetylase 1 and 
2, a MIDEAS corepressor protein, otherwise known as ELMSAN1 and also DNTTIP1.  The ELM-SANT 
domain units act to scaffold this HDAC and given that protein lysine acetylation plays a key role in 
controlling gene expression, ELMSAN1 is thus also involved in transcription binding and activation (Itoh 
et al., 2015). Furthermore, HDACs can be targeted by selective histone deacetylase inhibitors to find those 
with anti-cancer and anti-inflammatory properties and present a therapeutic avenue of research (Bantscheff 
et al., 2011). This finding, along with the altered DNA methylation state of the ELMSAN1 gene in smokers, 
may strengthen the role of epigenetic regulation in disease, especially in those caused by tobacco use. 
 
The 610 DMPs meeting the Bonferroni genome-wide significance threshold were located in roughly 305 
genes. To better understanding the biological mechanisms implicated by smoking, these were inputted into 
the STRING database. This web tool looks for association networks between the gene’s protein products 
based on evidence of fusion, co-expression, co-occurrence, presence in the same neighbourhood or from 
text mining.  This showed 134 interactions between the encoded proteins at the highest confidence threshold 
of 0.9, and this association network is shown in Figure 3.1.2. 
 
STRING also shows any KEGG pathways in which the inputted proteins are involved and these 
relationships are displayed within the interaction network. One example includes the eight proteins of 
GNG7, GNG12, GNAQ, KCNQ1, AKT3, CACNA1D, ITPR1 and ADCY9 which are involved in the 
cholinergic synapse. The corresponding neurotransmitter, acetylcholine, plays a critical  part  in  brain  
maturation  and  is  detectable  even before neurulation,  much  like nicotinic acetylcholine receptors 
(nAChRs). Acetylcholine also later promotes the transition from replication to differentiation and thus 
modulates neuronal development by promoting or preventing apoptosis. This continues into adolescence, 
a time most smokers begin using tobacco (Slotkin et al., 2004). Nicotine enhances cholinergic synaptic 
transmission by activating presynaptic nAChRs that then increase presynaptic calcium concentration which 
in part explains the excitatory effects of nicotine on the central nervous system and its highly addictive 
nature. Additionally, nicotine impacts cholinergic signalling within key nodes of the reinforcement circuitry 
and learning. This suggests differential methylation at these loci thus may be a product of nicotine and its 
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indirect promotion of acetylcholine and dopamine neurotransmitter release as most of these genes are also 
implicated at the dopaminergic synapse. AKT3, KCNQ1, CACNA1D, GNAQ and ADCY9, along with 
SCN7A, MYH6, CACNA2D2 and CACNA2D4 were also implicated in the adrenergic signalling in the 
cardiomyocyte pathway. Acute sympathetic stimulation of cardiac adrenergic receptors (ARs) is necessary 
for the appropriate output of the heart but when this becomes chronic a number of complications may arise 
that is detrimental to health and may induce apoptosis and cardiomyocyte hypertrophy (Lohse et al., 2003). 
Figure	3.1.2.:	STRING	interaction	network	of	the	134	interacting	proteins	encoded	by	the	genes	enclosing	
smoking-associated	DMPs	seen	at	a	Bonferroni	genome-wide	significance	threshold.	Only	shows	
interactions	that	meet	the	highest	confidence	threshold,	with	an	interaction	score	of	0.9.	Lines	are	
coloured	by	the	type	of	evidence	the	interaction	is	based	on.	Red	-	presence	of	fusion,	Green	-	
neighborhood	evidence,	Blue	-	cooccurrence,	Purple	-experimental,	Yellow	-	textmining	evidence,	Light	
blue	-	database,	Black	–	coexpression.	
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Decreased methylation of such sites may be linked to the increased risk of heart disease found in smokers. 
DNA methylation changes may then be able to reflect the signals stimulated by nicotine and tobacco use. 
  
Another enriched KEGG pathway is that of platelet activation in which genes ITGA2B, AKT3 and F2RL3 
are involved. Smoking is a major risk factor for coronary thrombosis and seems to impact the hemostatic 
process that maintains circulatory integrity after vascular injury. One way this occurs is through altered 
platelet function. Two distinct pathways occur during thrombus formation which may initiate platelet 
activation. The first occurs through exposure to subendothelial collagen, resulting in adhesion of platelets 
to the site of injury. The second involves tissue factors that establish a proteolytic cascade that produces 
thrombin. Thrombin then cleaves and activates receptors on the surface of platelets. Activated platelets in 
turn drive further thrombus formation. Cigarette smoke contributes to both pathways and the resulting clots 
seen in smokers appear to be more resistant to thrombolysis. Two key factors that contribute to the 
activation of these pathways is the free radical-mediated oxidative stress and loss of NO protection 
associated with smoking (Barua and Ambrose, 2013). Thus, differences in methylation in the ITGA2B, 
AKT3 and F2RL3 genetic loci of smokers may be related in the process of platelet activation when 
responding to the environmental stress of cigarette smoke.  
 
With this said however, the biological processes affected by smoking are certainly not limited to the 
synapses and platelets and these are just two of the most strongly enriched pathways. The fact that just the 
top 664 genome-wide significant DMPs inputted into the database can show the severe and far-reaching 
impact of smoking on health suggests that changes in DNA methylation are important biomarkers of such 
diseases. It then makes sense that so many KEGG pathways, ranging from regulation of the actin 
cytoskeleton to Huntington’s disease, be associated with smoking-related genes given the widespread 
impact it has on the methylome. 
 
3.2. Current vs Former Smokers 
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A similar trend of smoking-induced methylome changes were seen when comparing same-sized groups of 
current and former smokers whereby 826 probes were differentially methylated at a cutoff of 0.05 after 
FDR adjustment for multiple testing. 137 DMPs also remained significant after bonferroni correction, with 
a cutoff of 5.76 x 10-8. Figure 3.2.1. summarizes the adjusted P-values and effect sizes for the loci seen in 
this comparison, showing 513 hypomethylated and 313 hypermethylated CpG sites. Again, the strongest 
signals were seen in the AHRR, RARA, F2RL3 genes, the 2q37.1 region and others that have been well 
characterized (Joehanes et al., 2016). However, for all of these sites, both their significance values and 
effect sizes are much smaller when using former smokers rather than current smokers, suggesting some 
reversal of DNA methylation change upon cessation.  
 
Of the total 826 identified DMPs, 222 were not observed, i.e. were not statistically significantly 
differentially methylated, when comparing the same current smokers to never smokers. As seen in Figure 
Figure	3.2.1.:	Summary	of	826	significant	CpG	sites	differentially	methylated	between	current	and	former	
smokers	at	false	discovery	rate	P	<	0.05.	Red	line	indicates	Bonferroni	threshold.	Each	CpG	site	is	represented	
by	significance	as	shown	by	their	–log(P-value)	values	(y-axis)	and	effect	size	and	direction	(x-axis),	the	mean	β	
value	difference	between	groups.	Associations	are	colour-coded	in	reference	to	the	chromosome	the	CpG	site	
is	located	on.	
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3.2.2., 191 of these sites showed greater differences in DNA 
methylation between current and ex-smokers than there was 
between current and never smokers. Here, sites that were 
hypomethylated in current smokers compared to never 
smokers are in fact hypermethylated in former smokers 
when compared to the same never smokers and vice versa. 
For these sites, perhaps smoking cessation not only caused 
a reversal of smoking-related changes but this may go so far 
as to surpass non-smoker levels. For the remaining 31 sites, 
little difference is observed in the methylation levels 
between current, former ad never smokers and effect sizes 
for these sites remain around zero. This suggests that these 
sites simply met the FDR threshold when comparing current 
and former smokers by chance. 
 
In general, sites where this phenomenon was the most 
obvious were also the sites with the strongest effect sizes in 
the current and never smoker observation.  This suggests 
that these sites are more susceptible to changes in DNA 
methylation as a response or reflection of smoking status. A 
notable outlier is cg11025972 located on chromosome 13. 
This site has a near zero effect size between current and 
never smokers but showed obvious differences in DNA 
methylation when comparing current and former smokers as 
well as former and never smokers. Thus, this site had similar 
Beta-values for current smokers and non-smokers but was 
hypermethylated in former smokers. This site lied within an 
unannotated region of the genome so, using the humarray 
Figure	3.2.2.:	Summary	of	effect	sizes	for	222	
DMPs	observed	when	comparing	current	and	
former	smokers	but	not	between	current	and	
never	smokers.	
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package (Cooper, 2017), the closest gene symbol was found to be SOX1. This codes for a transcription 
factor involved in the neurogenesis of the central nervous system. It is particularly expressed in the striatum, 
a major component of the reward system, receiving glutaminergic and dopaminergic inputs (Guth & 
Wegner, 2008). This system is hugely impacted when a person ceases smoking and hypermethylation of 
this region may be related to the withdrawal symptoms ex-smokers experience. 
 
3.3. Former vs Never Smokers 
 
The decreased number of significantly differentially methylated sites seen when comparing current and 
former smokers as opposed to current and never smokers suggests that smoking-induced methylation is 
reversible upon smoking cessation and this has been shown in several studies (Tsaprouni et al., 2014 and 
Guida et al., 2015). To further test this, another model was run to compare methylation between the 175 
former and 175 never smokers used previously. This revealed 17 CpG sites with significant DNA 
methylation differences, with only 7 meeting the Bonferroni significance threshold (Figure 3.3.1.). All of 
Table	3.3.1.:	17	DMPs	associated	with	former	smoking	(former	vs	never	smokers)	
Illumina	
Probe	ID	
Chr	
Number	
Chromosome	
position	(bp)	
Design	
Type	
UCSC	
Gene	
Name	
UCSC	Gene	
Region	
Present	in	
450K	
Array	
FDR	
Adjusted	P	
Value	
Mean	
Effect	
Size	
cg14391737	 11	 86513429	 II	 PRSS23	 5'UTR;Body	 FALSE	 1.30E-15	 -0.07		
cg21566642	 2	 233284661	 I	 	  TRUE	 3.67E-13	 -0.07		
cg06644428	 2	 233284112	 I	 	  TRUE	 2.02E-11	 -0.05		
cg01940273	 2	 233284934	 II	 	  TRUE	 2.67E-11	 -0.05		
cg05575921	 5	 373378	 I	 AHRR	 Body	 TRUE	 6.13E-11	 -0.06		
cg03636183	 19	 17000585	 II	 F2RL3	 Body	 TRUE	 5.12E-05	 -0.04		
cg22812571	 2	 233286229	 II	 	  FALSE	 7.74E-05	 -0.05		
cg00475490	 11	 86517110	 II	 PRSS23	 5'UTR;Body	 FALSE	 6.43E-03	 -0.02		
cg16047567	 1	 12664243	 II	 DHRS3	 Body	 TRUE	 7.95E-03	 -0.02		
cg01692968	 9	 108005349	 II	 	  TRUE	 1.90E-02	 -0.03		
cg18110140	 15	 75350380	 II	 	  FALSE	 1.90E-02	 -0.03		
cg17739917	 17	 38477572	 II	 RARA	 5'UTR	 FALSE	 1.90E-02	 -0.04		
cg16841366	 2	 233286192	 II	 	  FALSE	 2.41E-02	 -0.05		
cg25189904	 1	 68299493	 II	 GNG12	 TSS1500	 TRUE	 2.41E-02	 -0.04		
cg15342087	 6	 30720209	 II	 	  TRUE	 2.41E-02	 -0.02		
cg15420926	 8	 132929147	 II	 EFR3A	 Body	 TRUE	 3.27E-02	 -0.01		
cg23771366	 11	 86510998	 II	 PRSS23	 TSS1500	 TRUE	 3.45E-02	 -0.03		
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these sites were also seen in the current vs never smoker model and this small number of significant hits 
suggest that almost all change to the epigenome caused by smoking becomes insignificant when quitting, 
especially as the effect sizes of the 17 DMPs were minimal, ranging from -0.069 to -0.014. Furthermore, 
no site had a higher significance than 1.30 x 10-15 after FDR adjustment as shown in Table 3.3.1. 
 
However, this does show that there is a long-lasting effect on DNA methylation at certain sites that remains 
even once smoking has ceased. Also, given that all but one DMP was hypermethylated in former smokers, 
this suggests that DNA hypomethylation represents more persistent changes to the methylome than those 
involving hypermethylation. The strongest site observed here is cg14391737 on chromosome 11, located 
within the serine protease 23 (PRSS23) gene along with multiple other DMPs. PRSS23 is a member of the 
trypsin family of serine proteases and coordinates many physiological functions, including the immune 
Figure	3.3.1.:	Summary	of	17	significant	CpG	sites	differentially	methylated	between	former	and	never	
smokers	at	false	discovery	rate	P	<	0.05.	Red	line	indicates	Bonferroni	threshold.	Each	CpG	site	is	
represented	by	significance	as	shown	by	their	–log(P-value)	values	(y-axis)	and	effect	size	and	direction	
(x-axis),	the	mean	β	value	difference	between	groups.	Associations	are	colour-coded	in	reference	to	the	
chromosome	the	CpG	site	is	located	on.	
		
36	
response and blood coagulation. Changes in the methylation state of this gene may contribute to the known 
protease-antiprotease imbalance observed in the emphysema of smokers. This causes an increased number 
of neutrophils and macrophages to be induced, causing these cells to release proteolytic enzymes that are 
not completely inhibited by antiproteases. These in turn lead to damage of connective tissues within the 
lung and has also been implicated in chronic obstructive pulmonary disease (COPD), a disease very closely 
associated to tobacco use. There is also strong evidence for this hypothesis in those with antitrypsin 
deficiency as it is the main inhibitor of neutrophil elastase (Abboud and Vimalanatha, 2008). However, 
there is a potential role of macrophage proteases in those without such a deficiency and serine proteases 
have been shown to contribute to elastolysis by alveolar macrophages in vitro, although it is difficult to 
identify a single protease that causes such lung destruction (Russell et al., 2002). Although this analysis 
was carried out on whole blood samples, the fact that former smokers had high estimates of monocyte 
number may in part explain the strong significance of PRSS23 when comparing former and never smokers. 
It may also suggest a prolonged impact of smoking on protease activity, even after smoking cessation.  
 
Another point to note in this comparison is the presence of one site, cg16047567, located in the DHRS2 
gene on chromosome 1. When comparing current and never smokers this site did not seem very important, 
ranking much lower on the list of DMPs compared to stronger signals but seems to one of the few sites that 
remain significantly differentially methylated after cessation. Dehydrogenase/Reductase 2 (DHRS2) codes 
for the Hep27 protein and is involved in carbonyl reductase (NADPH) activity. Smoking has been shown 
to stimulate the production of reactive oxygen species (ROS) which in turn causes oxidative stress and 
consequently many other related pathologies of the cardiovascular system. Some ROS-generating NADPH 
oxidases have been suggested to produce ROS and the reductive reaction of the Hep27 enzyme may work 
to prevent the toxic action of such species by converting them to less toxic compounds and thus help quench 
the effects of oxidative stress (Monge et al., 2009). The hypomethylation of such a site in former smokers 
compared to never smokers may then be related to the process.  
 
The presence of DMPs in AHRR, F2RL3, RARA and intergenic loci in the 2q37.1 region when comparing 
former and never smokers suggests that these genes also become permanently differentially methylated in 
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those who have smoked and represent a long-term biomarker of past exposure to smoking which has already 
been shown for AHRR and F2RL3 (Shenker et al., 2013).  
 
3.4. Differentially Methylated Regions 
 
DNA methylation change at individual CpGs often has a high dependence on its regional context and thus 
levels of methylation tend to correlate with neighbouring CpG sites. This co-methylation occurs in sites 
within close proximity to eachother and this is strongest for sites up to 1000bp from one another and 
especially in the context of CpG islands (Eckhardt et al., 2006). Regional clusters of neighboring CpGs that 
are differentially methylated with smoking are termed differentially methylated regions (DMRs) and may 
help better understand the biological processes affected by smoking and how the process of global  DNA 
methylation change might occur. Using the DMRcate package in R, 836 DMRs were identified between 
current and never smokers through kernel smoothing and these again spanned the entire genome, as 
0.090 -0.053
-5
 
Figure	3.4.1.	Genome-wide	distribution	of	836	differentially	methylated	regions	between	current	and	
never	smokers.	DMRs	are	colour	coded	in	relation	to	the	mean	beta	fold	change	within	the	region	with	red	
representing	negative	associations	and	blue	showing	positive.	
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expressed in Figure 3.4.1. The 836 DMRs included 4806 individual CpG sites, 1457 of which were DMPs 
found to be differentially methylated between current and never smokers suggesting only a 28.03% 
coverage of the 5198 smoking-related DMPs in these DMRs. The chromosomal coordinates of the 836 
DMRs were inputted into the Genomic Regions Enrichment of Annotations Tool (GREAT) online (McLean 
et al, 2010). This is particularly good for assigning biological meaning to non-coding genomic regions by 
analyzing annotations of nearby genes and is useful here given that almost a quarter of the identified DMPs 
were not annotated to a coding gene. GREAT also incorporates 20 different ontologies. Focusing on the 
enriched health-related ontologies, 3 diseases were found to be associated with the inputted smoking 
DMRs, including alpha 1-antitrypsin deficiency, crescentic glomerulonephritis and myelofibrosis. 
 
Firstly, alpha 1-antitrypsin deficiency (A1AD) is a rare genetic condition in which decreased alpha-1 
antitrypsin activity in the blood and lungs often leads to panacinar emphysema or COPD in adult life, 
especially in those exposed to cigarette smoke (Needham, 2004). Second, crescentic glomerulonephritis 
(RPGN) is a condition of the kidney characterized by rapid renal failure and with glomerular crescent 
formation involving layers of proliferating skin. In more than 50% of cases it is associated with another 
underlying disease such as Goodpasture syndrome (GPS). GPS is a rare autoimmune disease where the 
immune system attacks the basement membrane of the lung and kidneys and is likely caused by insults to 
the blood vessels connecting the lungs and heart, and one such possible insult is cigarette smoking (Greco 
et al., 2015). Lastly, myelofibrosis is a fairly rare cancer of the bone marrow where proliferation of an 
abnormal clone of hematopoietic stem cells leads to the replacement of marrow with scar tissue (Tefferi, 
2014). Smoking can cause up to a 25% increase in peripheral blood leukocytes and has been shown to 
stimulate the bone marrow by shortening the transit time of polymorphonuclear leukocytes (Eeden and 
Hogg, 2000). Although not directly linked to smoking, these diseases all show some association between 
their pathology and cigarette smoke exposure and may help in understanding the downstream consequences 
on health caused by DNA methylation change in these particular DMRs. With that said, the lack of expected 
disease ontology is likely due to the small coverage of CpGs included within the microarray. The human 
genome has approximately 28 million CpG sites meaning the EPIC array only reflects a minute fraction of 
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5-mC DNA methylation. The accuracy of kernel smoothing in estimating real regions of differential 
methylation will thus be greatly hindered by this.   
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4. Dosage Effects 
 
It is clear through the qualitative analysis of the previous chapter that smoking has a huge impact on DNA 
methylation, especially in current smokers. What is not clear are the factors that contribute to methylome 
variation in the same group of current smokers. Thus, in this chapter a more quantitative look at the impact 
of cigarette smoke on DNA methylation was used and considered the effects of dosage. This involved 
running linear models between transformed DNA methylation beta values, termed M-values, and data on 
number of cigarettes smoked per day and years spent smoking. This was done using 175 participants who 
currently smoked in wave 3 of Understanding Society, the same used in the qualitative linear models, as 
DNA methylation changes are known to be reversed in former smokers and thus may negatively impact the 
statistical strength of the model. These data were inputted as continuous, numeric variables in the design 
matrix with age, sex, white blood cell counts and batch as covariates. Methylation data was also restricted 
to the 5198 significant DMPs identified between current and never smokers to prevent any spurious 
associations. 
 
4.1. Duration 
 
The measure of duration used in these analyses was calculated by subtracting the age participants started 
to have first started smoking, a single time-point variable from wave 3, from their age at the time of blood 
collection. This gave the number of total years spent smoking which was then used in the linear model 
alongside the other stated variables. This initially only gave 1 significant association between duration and 
DNA methylation change, in the cg2030125 probes on chromosome 5, with an FDR adjusted P-value of 
just 0.02. 
 
However, when looking at the interdependence between duration and other variables within the model a 
high amount of correlation was found, at 0.94, between years spent smoking and age. This makes sense 
given that most people start smoking in their teens, where the mean age of smoking initiation for current 
smokers was 16.78 ± 4.72. Thus, the older a smoker is the longer they have smoked and this hinders the 
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duration model greatly. To counteract this, age was then removed from the model as the two variables 
supply quite redundant information when together given their correlation and thus removal did not 
drastically impact the R-squared value. Once this was done 1331 significant DMPs were found to be 
associated with years spent smoking, although it is not completely clear whether these sites are differentially 
methylated with age instead or in fact both.  
 
4.2. Epigenetic Age and Smoking Duration 
 
To understand which of the 5198 smoking associated probes, seen when comparing current and never 
smokers, are in fact associated with age an age-only model was run using the 175 non-smokers used 
throughout these analyses. This yielded 2020 sites with an FDR adjusted P-value below 0.05, compared to 
1422 age-associated sites seen when using current smokers. Furthermore, the top sites seen in the current 
smoker age model were much the same as those seen in the duration model but not the same as in the never 
smoker age model. For example, the most significantly associated probe with duration, cg19965693, 
located in the IFIH1 gene, was much further down the list, being the 486th strongest age-associated site in 
never smokers. This suggests that differential methylation at these sites are in fact more a consequence of 
smoking duration and not age and thus works to demonstrate the huge impact of smoking on the methylome 
whereby tobacco is a stronger driver of epigenetic modifications.  
 
To further study the relationship of DNA methylation with age and smoking duration, the age of the 175 
current smokers was predicted using DNA methylation data. Many different measures to do this have been 
created and used within the literature using a wide range of tissues but the most accurate thus far, especially 
in whole blood, seems to be Horvath’s epigenetic clock (Horvath, 2013). The predicted ages and actual 
ages of the currently smoking participants had a correlation of 0.88. The age acceleration of these same 
participants, or difference in actual age and DNA methylation age, was then calculated and ranged widely 
from -15.46 to 23.53 at the two extremes, although most estimations were much closer to the chronological 
age of the participants. Here, quite a strong negative trend of -0.69 was observed between age acceleration 
and actual age where younger participants tended to have underestimated predicted ages and older 
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participants had overestimated predicted ages. Interestingly, this occurrence was more pronounced in non-
smokers who had a correlation of -0.76 between age acceleration and actual age and more still in former 
smokers who had a correlation of -0.79. It is unclear at present why this occurs and may suggest that the 
Horvath clock does not fit well on EPIC methylation array data or that the missing probes from the 450K 
array on which the clock was built might have some impact. Another reasoning might be an issue within 
the Understanding Society data itself. In the latter, perhaps a “survival bias” is present where those that 
have survived to old age are more likely to be healthier and generally biologically younger than others who 
had not reached old age. With this reasoning perhaps smokers do not tend to reach older age and thus do 
not display survival bias to the same degree as non-smokers, explaining the lower correlation of smoker’s 
age with age acceleration. 
 
When comparing age acceleration with years spent smoking a similar negative trend was observed between 
the two. This would initially suggest that the DNA methylation age acceleration of early smokers is reversed 
with duration but this clearly is not the case but a consequence of the strong correlation between duration 
and age. Taken together it is clear that age and duration are highly intertwined but given the strong 
associations of smoking with DNA methylation it is acceptable to assume that by dropping age from the 
model, duration-associated sites can be observed and insights into the impact of dosage on the methylome 
can be made.  
 
4.3. Duration-related DMPs 
 
The FDR adjusted P-values and estimated log2-fold changes of the 1331 duration-associated DMPs are 
summarized in Figure 4.3.1. and the top 10 hypomethylated and 10 hypermethylated sites are shown in 
Table 1. The top hit, with an adjusted P-value of 4.91 x 10-15 was cg19965693, located upstream of the TSS 
in the IFIH1 gene on chromosome 2. The IFIH1 gene encodes the Interferon Induced with Helicase C 
Domain 1 protein and is also known as Melanoma Differentiation-Associated protein 5. It functions as a 
pattern recognition receptor (PRR) that senses viruses and is consequently an essential part of the immune 
system (Takeuchi and Akira, 2008). Antibodies against MDA5 are associated with amyopathic 
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dermatomyositis with rapidly progressive interstitial lung disease (Fiorentino et al., 2011), providing a link 
between the hypomethylation of this CpG site and smoking duration. Furthermore, inhibiting DNA 
methylation has been shown to induce the response of such interferons in cancer through dsRNA sensors 
(Chiappinelli et al., 2015). Given that both age and smoking are risk factors for a number of cancers, 
differential methylation observed at this gene may then relate to interferon function and thus strengthens 
the importance of DNA methylation, among other mechanisms, in controlling health. Furthermore, as this 
differential methylation is highly associated with smoking duration, perhaps this correlates with the extent 
of health impacts caused by cigarette smoke.  
  
Table	4.3.1.:	Top	10	hypomethylated	and	hypermethylated	probes	associated	with	smoking	duration	
Illumina	
Probe	ID	
Chr	
Number	
Chromosome	
position	(bp)	
Design	
Type	
UCSC	Gene	
Name	
UCSC	Gene	
Region	
Present	
in	450K	
Array	
FDR	
Adjusted	
P	Value	
Estimated	
Log2	Fold	
Change	
Hypomethylated	in	current	smokers	
cg19965693	 2	 163175743	 II	 IFIH1	 TSS1500	 FALSE	 4.91E-15	 -0.02		
cg16267679	 2	 145278615	 II	 LINC01412;ZEB2	 TSS1500;TSS1500	 FALSE	 2.75E-11	 -0.02		
cg00602811	 2	 145278564	 II	 ZEB2	 TSS1500	 TRUE	 2.75E-11	 -0.02		
cg18826637	 2	 145116633	 II	 	  TRUE	 1.13E-10	 -0.03		
cg21323642	 22	 31709724	 II	 	  FALSE	 2.10E-09	 -0.01		
cg12919873	 21	 38929815	 II	 	  FALSE	 2.92E-09	 -0.02		
cg03834786	 7	 80571772	 II	 	  FALSE	 3.31E-09	 -0.01		
cg00573770	 2	 145278485	 I	 ZEB2	 TSS1500	 TRUE	 9.91E-09	 -0.02		
cg19344626	 19	 16830749	 I	 NWD1	 TSS200	 TRUE	 1.68E-08	 -0.02		
cg11649376	 12	 81473234	 II	 ACSS3	 Body	 TRUE	 1.68E-08	 -0.01		
Hypermethylated	in	current	smokers	
cg04738965	 3	 147127662	 I	 ZIC1	 1stExon;5'UTR	 TRUE	 2.02E-09	 0.02		
cg15466862	 13	 112722333	 I	 SOX1	 1stExon	 TRUE	 2.55E-08	 0.02		
cg26422458	 1	 79472452	 I	 ELTD1	 5'UTR;1stExon	 TRUE	 3.53E-08	 0.02		
cg10906284	 12	 63544430	 I	 AVPR1A	 1stExon	 TRUE	 3.53E-08	 0.02		
cg23621097	 17	 1962236	 I	 HIC1	 3'UTR	 TRUE	 7.00E-08	 0.02		
cg19942495	 17	 32484027	 II	 ACCN1	 TSS1500	 TRUE	 9.86E-08	 0.01		
cg02926165	 5	 3595963	 II	 IRX1	 TSS1500	 FALSE	 9.96E-08	 0.02		
cg17953764	 4	 48492845	 I	 ZAR1	 1stExon	 TRUE	 1.04E-07	 0.01		
cg24125828	 6	 32117049	 I	 PRRT1	 Body	 TRUE	 2.02E-07	 0.02		
cg16001722	 6	 127836159	 II	 C6orf174	 Body	 TRUE	 2.09E-07	 0.02		
 
When comparing age-associated and duration-associated DMPs, 353 loci that were related to time spent 
smoking were not significantly differentially methylated with age at an FDR threshold of 0.05. The most 
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commonly occurring genes within these probes included four in the well characterized smoking-associated 
gene of AHRR and another four in the less reported SLC24A3 gene on chromosome 20. SLC24A3 is a 
potassium-dependent sodium/calcium exchanger on the plasma membrane. Excess salt intake has been 
implicated in the pathology of hypertension and one study showed epistatic interactions of SNPs in 
SLC24A3 with pressure-natriuresis (Citterio et al., 2011). Given that smoking increases blood pressure, the 
hypomethylation of these sites with increasing duration may provide a link between this disease and 
calcium homeostasis.  
 
The 353 CpG “duration-only” sites with available annotation were located in roughly 236 genes. To better 
understand the mechanisms these genes are involved in, they were inputted into the STRING database to 
visualize any interactions between their protein products. At the highest confidence, with a minimum 
required interaction score of 0.9, 53 interactions were found as shown in Figure 4.3.2. 
 
Figure	4.3.1.:	Summary	of	1331	significant	CpG	sites	differentially	methylated	with	smoking	duration	at	false	
discovery	rate	P	<	0.05.	Red	line	indicates	Bonferroni	threshold.	Each	CpG	site	is	represented	by	significance	
as	shown	by	their	–log(P-value)	values	(y-axis)	and	effect	size	and	direction	(x-axis),	the	mean	β	value	
difference	between	groups.	Associations	are	colour-coded	in	reference	to	the	chromosome	the	CpG	site	is	
located	on.	
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These interactions are involved in a number of KEGG pathways. Firstly, NRP1, EPHA7, SEMA7A, NCK2, 
RAC1 and PAK4 are all important in axon guidance. Some of these, especially members of the semaphorin 
family like SEMA7A, make up molecules that guide the outgrowth of axons, called axonal guidance cues. 
These in turn promote normal alveolar growth and many lung disease have been characterised by damage 
to the alveolar, linking this gene function with disease phenotypes caused by smoking (Vadivel et al., 2013). 
One such disease is bronchopulmonary dysplasia (BPD). This suggests that changes in DNA methylation 
might act as a biomarker for BPD and other smoking-related diseases. Furthermore, given the association 
of these sites with dosage, perhaps this can provide a quantifiable risk predictor to such diseases. 
 
Another interesting KEGG pathway is glutathione metabolism which ANPEP, MGST1, LAP3 and GGT1 
are involved in. Smoking causes damage to respiratory tract tissues and it is known that glutathione and 
related thiols can help perturb this and is an antioxidant component of the tract lining. This occurs when 
Figure	4.3.2.:	STRING	interaction	network	of	the	53	interacting	proteins	encoded	by	the	genes	enclosing	
duration-associated	DMPs	seen	at	a	FDR	significance	threshold	and	not	associated	with	age.	Only	shows	
interactions	that	meet	the	highest	confidence	threshold,	with	an	interaction	score	of	0.9.	Lines	are	
coloured	by	the	type	of	evidence	the	interaction	is	based	on.	Red	-	presence	of	fusion,	Green	-	
neighborhood	evidence,	Blue	-	cooccurrence,	Purple	-experimental,	Yellow	-	textmining	evidence,	Light	
blue	-	database,	Black	–	coexpression.	
		
46	
cigarette smoke reacts with glutathione-aldehyde derivatives and depletes the amount of available 
glutathione (Toorn et al., 2007). The duration-related changes to DNA methylation seen in genes related 
glutathione metabolism might then be related to the gradual worsening of health seen with increasing years 
of tobacco use.  
 
4.4. Intensity 
 
Another important dosage measure is that of intensity, or how much a person smokes as opposed to how 
long. To see if this influences DNA methylation, two measurements of intensity were used from the same 
currently smoking participants used above. The first is a single time-point variable from wave 3, the same 
year of the nurse visit where blood samples were collected. Here participants were asked how many 
cigarettes smoked per day. The second measurement involved taking an average of this same variable 
between waves J through to R of BHPS. This gave the mean number of cigarettes smoked by participants 
in the nine years leading up to wave 3 in Understanding Society.  
 
When the single time-point measure was used in the linear model, 33 CpG sites were significantly 
differentially methylated with number of cigarettes smoked. The strongest association was seen in the 
cg10590512 probe located in the DIO3;MIR1247 gene region on chromosome 14. Alternatively, the 
average measure of number of cigarettes yielded 23 DMPs with the most significant probe, cg25992330, 
located in the SPOCK2 gene on chromosome 10. The top ten loci for both measures are summarized in 
Table 2. It appears that the single time-point measure reflects a wider range of DNA methylation changes 
however the mean variable gave more significant P-values and thus suggests that by taking the mean a 
more sensitive and less noisy indication of cigarette smoke intensity can be measured. Therefore, this was 
used for the remaining analyses. 
 
The SEPT9 CpG site, cg11328665, was observed in both models suggesting that methylation at this site 
may be highly sensitive to intensity. 11 probes within this gene were also differentially methylated between 
current and never smokers, strengthening its association with smoking. SEPT9 codes for the Septin-9 
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protein. The v2 region of the gene’s promotor has been shown to become hypermethylated compared to 
healthy individuals in both the tissue of those with colorectal cancer as well as in the blood. This altered 
methylation pattern may indicate aberrant activation or repression of this gene and may have downstream 
consequences on pseudopod protrusion, tumor cell migration and invasion, processes known to rely on the 
function of SEPT9 (Tetzner et al., 2009). Smokers are known to have a significantly higher risk of 
developing colorectal cancer than those who do not smoke. Additionally, a dose-relationship between 
colorectal cancer risk with increasing number of cigarettes has also been reported, but only after 30 years 
of smoking (Botteri et al., 2008). Thus, this may provide a link between changes in  DNA methylation at 
SEPT9 with intensity of smoking and in turn cancer.  
 
 
Table	4.4.1.:	Top	10	hypomethylated	and	hypermethylated	DMPs	associated	with	smoking	intensity	
Illumina	
Probe	ID	
Chr	
Number	
Chromosome	
position	(bp)	
Design	
Type	
UCSC	Gene	
Name	
UCSC	Gene	
Region	
Present	
in	450K	
Array	
FDR	
Adjusted	
P	Value	
Estimated	
Log2	Fold	
Change	
Single	time-point	
cg10590512	 14	 102026939	 I	 DIO3;MIR1247	 TSS1500;TSS200	 FALSE	 3.15E-03	 0.02		
cg03440944	 7	 45023329	 II	 C7orf40	 Body	 TRUE	 1.90E-02	 -0.01		
cg11328665	 17	 75446304	 II	 SEPT9	 TSS1500;Body	 FALSE	 1.90E-02	 -0.01		
cg17567838	 6	 33167488	 II	 SLC39A7	 TSS1500;Body	 TRUE	 2.36E-02	 -0.01		
cg09945032	 3	 38871019	 II	 	  FALSE	 2.80E-02	 -0.01		
cg06532880	 5	 176731545	 II	 PRELID1;RAB24	 Body;TSS1500	 TRUE	 2.80E-02	 -0.01		
cg05575921	 5	 373378	 I	 AHRR	 Body	 TRUE	 2.80E-02	 -0.02		
cg03220447	 11	 19745293	 II	 NAV2	 Body	 TRUE	 2.80E-02	 -0.01		
cg11320225	 1	 161709963	 II	 	  FALSE	 2.80E-02	 -0.01		
cg17731696	 8	 66734530	 II	 PDE7A	 Body	 FALSE	 3.83E-02	 -0.01		
Mean	of	multiple	time	points	
cg25992330	 10	 73830099	 II	 SPOCK2	 Body	 FALSE	 1.23E-03	 0.01	
cg05575921	 5	 373378	 I	 AHRR	 Body	 TRUE	 1.29E-02	 -0.03	
cg26341457	 11	 72523885	 II	 	  FALSE	 1.29E-02	 -0.01	
cg10590512	 14	 102026939	 I	 DIO3;MIR1247	 TSS1500;TSS200	 FALSE	 1.29E-02	 0.02	
cg03707168	 19	 49379127	 II	 PPP1R15A	 Body	 TRUE	 1.37E-02	 -0.01	
cg11328665	 17	 75446304	 II	 SEPT9	 TSS1500;Body	 FALSE	 1.37E-02	 -0.01	
cg03440944	 7	 45023329	 II	 C7orf40	 Body	 TRUE	 1.37E-02	 -0.01	
cg09945032	 3	 38871019	 II	 	  FALSE	 1.37E-02	 -0.01	
cg07954423	 9	 130741881	 II	 FAM102A	 Body	 TRUE	 1.37E-02	 -0.01	
cg00475490	 11	 86517110	 II	 PRSS23	 5'UTR;Body	 FALSE	 1.37E-02	 -0.02	
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However, by far the site with the strongest association with mean number of cigarettes smoked, with an 
FDR adjusted P-value of 0.001, is cg25992330 located in the SPOCK2 gene. This encodes a member of a 
calcium binding proteoglycan family, important components of the extracellular matrix. It is also a known 
susceptibility gene for bronchopulmonary dysplasia, formerly known as chronic lung disease of infancy 
(Hadchouel et al., 2011) and this disease was also elucidated to in the enriched axon guidance KEGG 
pathway with duration DMPs.  
 
Clearly increasing number of cigarettes causes changes in DNA methylation at important disease-related 
genes associated with smoking. However, all other sites were very close to the 0.05 cutoff and thus raises 
concerns about the reality of their associations with smoking intensity. In fact, this suggests that intensity 
all together may not have much influence on DNA methylation and instead the drastically larger number 
of associations seen with smoking duration suggests that years spent smoking may have a far larger impact 
on the methylome. Nevertheless, this shows that different CpG sites, even those located in the same region, 
respond differently to duration and intensity. This may provide an insight into the different biological 
mechanisms at play when studying how environmental factors and dosage influence DNA methylation.  
 
4.5. Duration vs Intensity 
 
As there is such a large difference between duration and intensity in both the number and location of dosage-
related DMPs, the two were compared further. The aim of doing this was to better classify these differences 
and hopefully identify which dosage measure might be more important in DNA methylation. Firstly, Figure 
4.5.1. compares the distribution of significance values and log2-fold change estimates between duration 
and intensity for all 5198 smoking-associated CpG sites. These plots show far more significant changes in 
DNA methylation with duration compared to intensity as expressed before in the two models. However, 
the estimates of the log2-fold-change for each probe, which in a way gives a measure of effect size with 
increasing dosage, do not show such large differences. In fact, both dosage measures saw estimates that 
were very low in comparison to the more than 1.0 log2-fold changes seen when comparing current and 
never smokers but this may be a consequence of using continuous variables instead of categorical factors. 
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These log2-fold change estimates do show that the duration-associated DMPs had slightly larger estimates 
than intensity. It also shows that positive coefficients also tended to have larger estimates of log2-fold-
change and this seemed to be independent of their significance. Furthermore, both measures of dosage show 
a greater representation of negative over positive coefficients, but to a smaller extent when using intensity 
data. Given that hypermethylated sites in smokers tended to have modest significance values compared to 
the hypomethylated probes, this could suggest that the mechanism driving this change causes larger 
differences in DNA methylation and may, in a small way, explain why number of cigarettes smoked per 
day makes less of an impression on DNA methylation. Either way, by looking at these funnel plots it is 
clear that the number of significant DMPs does not fully reflect the actual, measurable changes to the 
methylome caused by increased duration or intensity. Instead it simply states how many probes met a 
certain threshold and this number is also highly sensitive to the covariates included in the model.  
 
To overcome this and further test the effects of duration and intensity on DNA methylation, the current 
smokers were split by quantiles into four equal-sized groups of 40 based on number of cigarettes smoked 
Figure	4.5.1.:	Funnel	plots	summarizing	the	associations	of	DNA	methylation	with	smoking	intensity	and	
duration	for	the	5198	smoking-associated	probes.	Each	CpG	site	is	represented	by	significance	as	shown	by	
their	–log(P-value)	values	(y-axis)	and	the	direction	and	change	in	DNA	methylation,	represented	by	their	
estimated	log2-fold	changes	(x-axis),	a	measure	of	effect	for	the	dosage	coefficient.	
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per day, and another four based on years spent smoking. Then, the difference in DNA methylation between 
each smoker group and an equal-sized sample of 40 never smokers, termed here as the absolute effect size, 
was calculated. By doing so it is possible to measure the extent of DNA methylation differences between 
non-smokers and smokers with varying dosage exposures. These differences were calculated using Beta-
values for the top 10 probes associated with years spent smoking in the duration groups and the top 10 
probes associated with mean number of cigarettes for the intensity groups. The total mean DNA methylation 
difference between the eight smoker groups and never smokers are outlined in Figure 4.5.2. 
 
This showed a relationship between increases in both duration and intensity and increased DNA 
hypomethylation in smokers compared to non-smokers, at least for the top 10 sites associated with each 
measure. However, duration was associated with a much greater change in DNA methylation compared to 
intensity. Here, absolute effect sizes across the duration quantiles ranged from 0.14 to -0.65 showing a huge 
decrease in DNA methylation, of almost 0.79, between those who have smoked less than 26 years and those 
having smoked more than 44 years. On the other hand, the absolute effect sizes between the intensity groups 
and never smokers ranged from -0.42 to -0.21. This shows a much smaller decrease in DNA methylation, 
Figure	4.5.2.:	Mean	absolute	effect	size	between	smokers	and	non-smokers	per	dosage	quantile.	
Shows	mean	difference	between	the	40	smokers	and	40	non-smokers	in	each	group,	calculated	using	
DNA	methylation	values	for	the	top	10	DMPs	associated	with	duration	(right)	and	intensity	(left).	
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around 0.21, between those who smoke less than 11.1 cigarettes a day and those who smoke more than 20. 
Furthermore, the steepest methylation difference for intensity was observed between the first and second 
quantile groups. Thereafter, smaller decreases in DNA methylation are observed which suggests that the 
methylome of those who smoke less than 11.1 cigarettes a day is less effected than those who smoke more 
but not by much. As for duration, changes in DNA methylation between smokers and non-smokers were 
more gradual, with similar decreases in absolute effect sizes with each increasing dosage group. This 
suggests DNA methylation is more highly correlated with years spent smoking than number of cigarettes 
smoked. Taken together, this analysis suggests that duration rather than intensity is more important in 
driving changes to the methylome and thus may be more influential in smoking-related illness in the cases 
where DNA methylation influences the expression of important health-associated genes. 
 
To look at the interplay between duration and intensity the analyses above were repeated, splitting the four 
duration quantiles into eight groups based on intensity, where four consisted of participants smoking less 
than 16 cigarettes per day and another four consisted of those who smoke more than 16. Equal sized samples 
of 15 participants were then used in each analysis and the same was carried out for intensity where the 
groups were split by who reported to have smoked for less or more than 35 years. The absolute effect size 
between these 16 groups and another subset of 15 non-smokers are outlined in Figure 4.5.3.  
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In all four scenarios increasing dosage led to DNA hypomethylation in smokers compared to non-smokers. 
However, duration again showed the biggest changes in DNA methylation with a steady decline in absolute 
effect size across years spent smoking. As for intensity, a steep decline in DNA methylation was again seen 
between the first and second quantiles but thereafter DNA methylation difference varied greatly and at 
some points even seemed to increase. This is likely caused by the small sample size used to calculate the 
average effect size between the intensity groups and never smokers. Here, increasing number of cigarettes 
seemed to have little impact on DNA methylation change and thus was not able to overcome this shortfall. 
Figure	4.5.3.:	Mean	absolute	effect	size	across	between	smokers	and	non-smokers	per	dosage	
quantile	split	by	median	duration	(top)	and	intensity	(bottom).	Shows	mean	difference	between	the	
15	smokers	and	15	non-smokers	in	each	group,	calculated	using	DNA	methylation	values	for	the	top	
10	DMPs	associated	with	duration	(bottom)	and	intensity	(top).	
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Increasing duration on the other hand still showed a strong negative trend with DNA methylation change 
despite the small group sizes.  
 
The two dosage measures seemed to make little impact on DNA methylation differences. The one exception 
to this being in those who had smoked for up to 26 years within the first quantile. Beta values for participants 
who fell into this group and also smoked more than 16 cigarettes a day were higher by around 0.11 than 
other participants who smoked less but for similar durations. This suggests than intensity only impacts 
DNA methylation in the early years of smoking and thus for the majority of cases it appears than intensity 
and duration are independent of one another. 
 
4.6. Predicting Smoking Duration 
 
Throughout this chapter it is clear that years spent smoking is highly correlated with DNA methylation 
levels at a number of CpG sites. This might then allow for smoking duration to be estimated using measures 
of DNA methylation at duration-associated sites. To attempt this, a similar procedure was used to that 
developed by Horvath for the well-known epigenetic age clock (Horvath, 2013). The general principle to 
this is to form a weighted average of DNA methylation at a number of duration-related CpG dinucleotides 
and then transform this into years spent smoking. This is done using a penalized regression model which 
uses an elastic net regularization approach to regress self-reported duration years from a sample of 85 
current smokers, termed as the training set, onto the 1331 EPIC array probes associated with duration. 
Elastic net regularization makes use of the “elastic net” that combines the L1 and L2 penalties of the lasso 
and ridge method and hence overcomes the limitations of many modelling techniques. The elastic net then 
automatically selects the CpG sites most associated with duration and these are then used in the prediction.  
 
The regression model was run using the glmnet package from R (Friedman et al., 2010). To do so, first a 
10 fold cross validation was carried out, using the cv.glmnet function, to find an estimate of the lambda 
parameter to be used. Then, a generalised linear model, with elastic net regularization, was fitted to the 
training set data using the glmnet function. This function uses a penalized maximum likelihood approach 
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and requires specification of the alpha parameter, which was set to 0.5 as the elastic net predictor was used, 
and the lambda value, which was set to 1.120921 as estimated by the cross-validation. This model then 
enabled the calculation of estimates for years spent smoking by using the usual predict function. This last 
step was carried out on methylation Beta-values from the other half of current smokers, the test set. The 
predicted and actual years since quitting are shown in Figure 4.6.1. 
 
This shows a correlation of 0.76 between the predicted and actual years spent smoking in former smokers. 
The mean difference between the actual and predicated duration values in this group was 0.31 with a 
standard deviation of 9.30. This variation is likely caused by the small sample size used when creating the 
model and thus DNA methylation data from a larger number of active smoker participants would likely aid 
in improving this prediction. Nevertheless, this predictor also showed some correlation with duration in 
former smokers, with a Pearson of coefficient of 0.43. This smaller correlation is likely a reflection of the 
reversal of DNA methylation changes that occurs when a person stops smoking. Together this suggests that 
this prediction has value as a biomarker of smoking duration and can be used to estimate the extent of 
Figure	4.6.1.:	Goodness	of	fit	for	predictor	of	years	spent	smoking.	Shows	actual	years	spent	
smoking	(x-axis)	against	predicted	years	spent	smoking	(y-xis).	Pearson	correlation	coefficient	=	
0.76.	
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changes to the methylome caused by duration. Furthermore, for disease-associated genes whose expression 
is influenced by DNA methylation, this model may even help predict risk to health caused by tobacco use. 
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5. Cessation 
 
The best tactic for preventing smoking-related illness is clearly to not smoke in the first place but given that 
there are still appropriately 1 billion smokers worldwide, the second best option is to quit smoking as soon 
as possible. By doing so the impact on the methylome associated with years of tobacco use may be 
minimized. In the third chapter, it was apparent that DMPs still exist when comparing former and never 
smokers and thus cessation may not completely recover DNA methylation to that of someone who has 
never smoked. It does however reduce the degree of differences between ex-smokers and non-smokers 
drastically, including changes to epigenetic loci located in important disease-associated genes. DNA 
methylation then is very sensitive to smoking status and thus may have potential as a biomarker for years 
of cessation. To further study this a number of analyses were carried out using the 356 participants of 
Understanding Society who stated in wave 3 that they had previously smoked but do not do so anymore. 
These were also selected on the availability of their cessation data which included self-reported variables 
on age of quitting. The number of years since cessation was thus calculated by taking the age of quitting 
and subtracting this from their age at the time of blood sample collection in wave 3 of the study.  
 
5.1. Cessation-related DMPs 
 
Years since quitting ranged from 1 to 66 years and this data had some correlation with both age (0.57) and 
smoking duration (-0.45). Despite this, age was kept in the model alongside sex, blood process day, batch 
and white blood distribution estimates to avoid any fictitious associations with cessation. First, a linear 
model was used to look at the relationship between DNA methylation levels and years since quitting 
smoking. This was restricted to the 5198 smoking-associated loci identified when comparing current 
smokers and participants who had never smoked. The model yielded 192 significantly differentially 
methylated sites with years since quitting, and the significance and log2-fold-change values of these sites 
are summarized in Figure 5.1.1. 171 of the sites became hypermethylated with years since quitting leaving 
21 hypomethylated sites.  This makes sense as a reversal of the huge surplus of hypomethylated probes 
seen in smokers compared to non-smokers. It also suggests that these sites gradually recover their 
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methylation states with increasing cessation years. Of the 192 DMPs, 82 were also associated with duration. 
This suggests that the process by which the reversal of DNA methylation changes occur may be related but 
is not simply the reverse process driving such changes with increasing duration and instead there are more 
factors at play here.  
 
The top 10 hypermethylated and 10 hypomethylated cessation-associated DMPs are shown in Table 1. The 
most strongly associated probe, cg05575921 within the AHRR gene, is also the most strongly associated 
site with smoking in general. Sites within this gene had weak associations with duration but had the second 
strongest association with intensity. Its presence as a cessation-related DMP may then be caused by the 
now zero number of cigarettes smoked by former smokers. This site also becomes hypermethylated very 
quickly after cessation for most participants, as show by a steep curve between Beta-values for this site and 
Figure	5.1.1.:	Summary	of	192	significant	CpG	sites	differentially	methylated	with	smoking	cessation	at	false	
discovery	rate	P	<	0.05.	Red	line	indicates	Bonferroni	threshold.	Each	CpG	site	is	represented	by	significance	as	
shown	by	their	–log(P-value)	values	(y-axis)	and	effect	size	and	direction	(x-axis),	the	mean	β	value	difference	
between	groups.	Associations	are	colour-coded	in	reference	to	the	chromosome	the	CpG	site	is	located	on.	
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years since quitting, strengthening the idea that DNA methylation at this site is influenced by number of 
cigarettes.  
 
Interestingly, sites located in the PRSS23 gene were also strongly associated with years of quitting and were 
also present in the DMPs between former and never smokers. The DNA methylation of sites in this gene 
may then be reversed very slowly after cessation. Furthermore, PRSS23 encodes the serine protease 23 
enzyme, and is responsible for a huge range of biological processes, including blood clotting, food 
digestion, infection fighting and fertilization (Neitzel, 2010). This then hints that the changes in DNA 
methylation observed at this gene may be linked to the increased good health seen in ex-smokers, especially 
after many years of cessation. Other strongly associated sites lied in the 2q37.1 intergenic region. The 
closest genetic feature, found using the nearest.gene function from the humarray CRAN  package, was 
Table	5.1.1.	Top	10	hypomethylated	and	hypermethylated	DMPs	associated	with	smoking	cessation	
Illumina	
Probe	ID	
Chr	
Number	
Chromosome	
position	(bp)	
Design	
Type	
UCSC	
Gene	
Name	
UCSC	Gene	
Region	
Present	
in	450K	
Array	
FDR	
Adjusted	P	
Value	
Estimated	
Log2	Fold	
Change	
Hypermethylated	in	current	smokers	
cg05575921	 5	 373378	 I	 AHRR	 Body	 TRUE	 3.35E-17	 0.027		
cg14391737	 11	 86513429	 II	 PRSS23	 5'UTR;Body	 FALSE	 5.27E-17	 0.018		
cg21566642	 2	 233284661	 I	 	  TRUE	 6.60E-17	 0.017		
cg16841366	 2	 233286192	 II	 	  FALSE	 2.33E-09	 0.014		
cg06644428	 2	 233284112	 I	 	  TRUE	 3.52E-09	 0.021		
cg01940273	 2	 233284934	 II	 	  TRUE	 4.42E-09	 0.010		
cg03636183	 19	 17000585	 II	 F2RL3	 Body	 TRUE	 4.42E-09	 0.009		
cg22812571	 2	 233286229	 II	 	  FALSE	 1.58E-08	 0.013		
cg00475490	 11	 86517110	 II	 PRSS23	 5'UTR;Body	 FALSE	 3.32E-08	 0.012		
cg11660018	 11	 86510915	 II	 PRSS23	 TSS1500	 TRUE	 4.35E-06	 0.007		
Hypomethylated	in	current	smokers	
cg09375092	 12	 26576047	 II	 ITPR2	 Body	 FALSE	 4.63E-04	 -0.010		
cg12803068	 7	 45002919	 II	 MYO1G	 Body	 TRUE	 4.86E-03	 -0.013		
cg08035323	 2	 9843525	 II	 	  TRUE	 6.96E-03	 -0.007		
cg10819708	 15	 90735422	 II	 SEMA4B	 5'UTR	 TRUE	 8.41E-03	 -0.003		
cg05009104	 7	 45002980	 II	 MYO1G	 Body	 FALSE	 1.39E-02	 -0.006		
cg02327909	 12	 53009774	 II	 KRT73	 Body	 FALSE	 1.63E-02	 -0.003		
cg07790294	 19	 928287	 II	 ARID3A	 5'UTR	 FALSE	 1.89E-02	 -0.003		
cg19459791	 15	 65363022	 II	 	  TRUE	 1.93E-02	 -0.004		
cg01756827	 20	 47923790	 II	 	  FALSE	 1.93E-02	 -0.005		
cg10874644	 5	 83898708	 II	 		 		 TRUE	 2.07E-02	 -0.006		
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ALPPL2, an alkaline phosphatase. Levels of this enzymes have been show to increase up to tenfold in 
cigarette smokers and cancer patients (Koshida et al., 1990) and thus with increased length of cessation 
these levels may fall and this again shows a possible link between the reversion of DNA methylation 
changes and the improved health, and reduced cancer risk, seen in former smokers compared to current 
smokers.  
 
Interestingly, other sites in genes strongly associated with smoking, such as ZMIZ1 and ELMSAN1, were 
not associated with cessation. In fact, DNA methylation of only a handful of smoking-related CpG sites 
seemed to be influenced by smoking cessation, leaving well over 5000 sites that were not related with years 
since quitting. One line of reasoning for this is that for these sites DNA methylation is permanently altered 
by tobacco use. This then suggests that the site-specific manner by which DNA methylation changes happen 
may actually be split into two distinct groups of reversible and permanent smoking-related DMPs. 
However, this would then suggest a huge surplus of permanently altered CpG sites but only 15 probes were 
found to be significantly differentially methylated between former and never smokers so this seems 
unlikely. A more plausible explanation relates to the fact that this this model looks into changes in DNA 
methylation across all years of smoking cessation, starting at 1 year. Perhaps some sites are reversed very 
early after quitting, within the first year where no such data is available. Thus, these sites would quite 
rightly not be associated with cessation in this analysis and instead the 192 identified DMPs show sites that 
have a longer time-span for reversal, taking some decades to be restored to anywhere near non-smoker 
levels. 
 
The 192 significantly associated probes with available annotation were located in 104 genes. To look at the 
relationship between these gene,s and more specifically their protein products, interactions were searched 
using the STRING database. This showed 21 of the 104 proteins interacted with at least one other inputted 
protein using the highest confidence threshold, where all interactions had a score of at least 0.9. This 
network is shown in Figure 5.1.2. and consists of 5 distinct clusters of proteins. Five of these proteins, 
including AKT3, HTRA2, ITPR2, TNF and BIRC3, were implicated in the apoptosis pathway from KEGG. 
In fact, one apoptotic pathway is directly mediated by the death receptor of the tumor necrosis factor (TNF) 
		
60	
receptor family. Lack of functional apoptotic pathways can lead to harmful cell proliferation and survival, 
a distinctive feature of cancer. Previous studies have seen aberrant methylation at important, apoptosis-
related CpG sites in cancer cell lines including that of the lung. These were located in the promotor regions 
of O-6-methylguanine-DNA-methyltransferase (MGMT), a DNA repair enzyme, and RAS-associated 
domain family protein 1A (RASSF1A), a tumor suppressor gene. Methylation of promotors is suggested to 
be a mechanism of gene silencing and tumorigenesis and in this case caused decreased DNA repair capacity 
and decreased cell cycle control in cells, leading to reduced apoptosis (Koutsimpelas et al., 2012). This 
shows that a strong link between differential DNA methylation and apoptosis exists. Furthermore, the fact 
that these genes are associated with cessation, and become hypermethylated with years since quitting, may 
mean effective apoptotic processes can be regained by stopping smoking and this in turn would lead to 
better health outcomes. The implication of pathways in cancer was also seen for these genes from KEGG, 
strengthening their associations with health. 
 
 
 
 
Figure	5.1.2.:	STRING	interaction	network	of	the	21	interacting	proteins	encoded	by	the	genes	enclosing	
cessation-associated	DMPs	seen	at	FDR	genome-wide	significance	threshold.	Only	shows	interactions	that	
meet	the	highest	confidence	threshold,	with	an	interaction	score	of	0.9.	Lines	are	coloured	by	the	type	of	
evidence	the	interaction	is	based	on.	Red	-	presence	of	fusion,	Green	-	neighborhood	evidence,	Blue	-	
cooccurrence,	Purple	-experimental,	Yellow	-	textmining	evidence,	Light	blue	-	database,	Black	–	
coexpression.	
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5.2. DNA Methylation with Years Since Quitting 
 
As stated, the linear model that compared DNA methylation and years of quitting can only reveal sites 
whose DNA methylation levels change with increasing time since quitting within former smokers. It does 
not show which of these loci are still significantly differentially methylated compared to never smokers nor 
at which year of cessation these loci might lose this significance. To counteract this the 356 participants 
used in these analyses were split by quantiles into five equal-sized groups, each containing 60 participants.   
 
After, linear models were repeated as before but this time used to compare each of these groups of former 
smokers, each with similar years since quitting smoking, to an equal sized reference sample of never 
smokers. This analysis was limited to the 192 cessation-associated probes identified before to ensure 
assumptions are only made about DNA methylation decay related to time since quitting. Figure 5.2.1. shows 
the number of DMPs observed between each cessation quantile and the non-smoker sample.  
Figure	5.2.1.:	Number	of	significantly	differentially	methylated	probes	seen	between	former	smokers	and	
non-smokers	per	cessation	quantile.	Each	group	of	60	former	smokers	were	seperated	based	on	years	
since	quitting	and	were	compared	to	an	equal	sized	group	of	non-smokers.	
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142 of the 192 cessation-related DMPs were differentially methylated with smoking status in at least one 
group. The largest number of significant DMPs observed were the 136 seen in former smokers who had 
quit between 1 and 7 years ago. This number then decreased to 52 in participants who quit between 7 and 
15 years and further still to just 2 DMPs in those quitting between 15 and 26 years before. Thereafter, no 
significantly differentially methylated CpG sites were found. This suggests that DNA methylation changes 
in participants with a cessation period longer than 26 years are almost completely reversed. Furthermore, 
the steepest drop in the number of significant DMPs occurs in the first 15 years of quitting. This shows that 
the differences in DNA methylation between ex-smokers and non-smokers are most apparent in those 
quitting for fewer years. It also suggests that the methylome may make an almost full recovery back to non-
smoker levels and that this largely occurs in the first two or three decades after cessation. However, it is 
important to note the impact of age on DNA methylation as the mean age gradually increased in each 
quantile group, from 55.01 to 66.48. There was also a correlation of 0.57 between age and years of cessation 
as stated before. Given that many age-related differences in DNA methylation have been observed there is 
still some chance that the differences observed with cessation are actually caused by the complex 
relationship between age and DNA methylation. However, with the inclusion of age in the models, and the 
fact that more than half of the cessation-assocatied DMPs were not seen in the age-only model, it is likely 
that the decrease in DMP number represents real cessation effects on smoking-related changes to the 
methylome. 
 
5.3. Quantifying Methylome Change Across Years Since Quitting 
 
It is hard to quantify the differences in DNA methylation with years since smoking cessation by simply 
stating the number of significant probes that met an FDR threshold. Significance measures can be highly 
sensitive to the linear model in question and make it difficult to study the real differences in DNA 
methylation at play. To overcome the absolute effect size was calculated between each group of former 
smokers, split by years since quitting, and non-smokers. For each of the five groups, DNA methylation 
levels were averaged across the 60 former smokers used and the absolute effect size was measured between 
these groups and the average DNA methylation of the never smoker reference sample. Absolute effect size 
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is the sum of these differences for the top 10 cessation-associated probes and these are shown in Figure 
5.3.1. along with the standard deviations for each quantile. For all five groups, the 10 probes were 
hypomethylated in former smokers compared to non-smokers. However, the degree of this 
hypomethylation decreases with increasing years of cessation, at least up to 36 years. In fact, there is a quite 
a strong linear relationship between DNA methylation differences at these 10 CpG sites and time since 
quitting, as shown in the first four quantiles. This suggests a strong association between DNA methylation 
and cessation length where absolute effect sizes return closer to 0 with increasing cessation, but only up to 
36 years. The fifth quantile, containing participants who stopped smoking from 36 to 66 years ago, shows 
a slight increase in hypomethylation compared to the fourth quantile of participants quitting 26 to 36 years 
ago. This may be a consequence of the large range of cessation years within this group as few participants 
in Understanding Society had quit more than 36 years ago. This measurement may also be hindered by the 
higher mean age within this group.  
Figure	5.3.1.:	Mean	absolute	effect	size	between	former	smokers	and	non-smokers.	Shows	mean	
difference	between	the	60	former	smokers	and	60	non-smokers	in	each	group,	calculated	using	DNA	
methylation	values	for	the	top	10	DMPs	associated	with	cessation.	
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Clearly measuring absolute effect size provides a good insight into the real effects of cessation on DNA 
methylation. However, this is also sensitive to outlying data and other factors. A better way to quantify the 
total methylation difference of former smokers is to use these 10 sites in the creation of a smoking index 
(SI), detailed in the following equation from Teschendorff’s work in 2015; 
 
 
 
This gives a measure of deviation from a normal reference, standardized by the deviation of DNA 
methylation, and takes into account the directionality of such changes. In this case the reference group 
consisted of the 60 non-smokers used in the above analyses, and was created using the DNAm Beta-values 
for the top n (10) number of cessation-related probes. Here, µc is the mean beta-value, and σc the standard 
deviation, for each probe across the reference samples. For any given s sample, Wc is +1 if the probe in 
question is hypermethylated and -1 if hypomethylated in former smokers across years since quitting. Βcs is 
the beta value of the CpG site c in sample s. This summation is over all 10 most strongly cessation-
associated DMPs and was calculated for all 356 ex-smoker participants. This is shown in Figure 5.3.2.  
 
The computed SI scores for the majority of former smokers was negative, showing the strong influence of 
previous smoking on DNA methylation. In general, there is more variation in smoking index scores in the 
early years of smoking cessation than those who have quit for longer periods of time. This suggests that 
smoking may cause increased variation in DNA methylation and this has been commented on before 
(Ambatipudi et al., 2016). As time since quitting increases, the SI scores of former smokers tends to get 
closer to a score of 0 meaning DNA methylation gets closer to non-smoker levels. It also supports the 
finding that sites become hypermethylated with years since quitting. This is shown in the small but real 
correlation of 0.25 between SI scores and length of cessation. There was also an even stronger correlation 
of -0.55 between duration dosage and the calculated smoking index scores. This supports the associations 
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between DNA hypomethylation and years spent smoking and again shows the huge impact of smoking on 
DNA methylation as well as the complexities in reversing duration-induced changes to the methylome. It 
also hints at an interaction between duration and cessation in their impact on DNA methylation. 
Furthermore, the mean SI score for each cessation quantile was calculated and again DNA methylation 
change decreases across the first four quantiles, consisting of participants with 1 to 36 years of smoking 
cessation. Clearly this is an effective biomarker in showing the decay of changes to the methylome upon 
quitting smoking and this is even sensitive enough to be observed in only 10 CpG sites. It also suggests 
that this reversal may not fully reach non-smoker levels, even after 36 years of cessation and supports 
previous findings showing similar results (Guida et al., 2015).  
 
5.4. Role of Duration in Cessation-related Decay 
Figure	5.3.2.:	Distribution	of	smoking	index	(SI)	scores	for	all	356	former	smoker	partipants..	Light	blue	
dots	represent	distribution	of	SI	scores	within	each	of	the	five	cessation	quantile	groups	(top	axis).	The	
mean	SI	score	for	each	group	was	calculated	and	shown	as	a	dark	blue	triangle.		
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Multiple sites associated with cessation were also 
associated with duration. For these sites, most are 
hypomethylated with increasing duration and 
hypermethylation with increasing years since quitting. 
Furthermore, previous studies have showed a 
relationship at some sites, such as those in the F2RL3 
and GPR15 genes, where methylation increases with 
cumulative exposure, i.e. pack years, and decreases with 
time since quitting (Wan et al., 2012). To try and 
replicate these findings in this study, the 356 former 
smokers were split into equal-sized groups based on 
quartiles for years of smoking and years since quitting. 
This created 16 groups with varying duration and 
cessation histories. Duration measures were used 
instead of cumulative exposure due to the weak 
associations of DNA methylation change with intensity. 
 
The sum of average DNA methylation was then 
measured for the three smoking-associated probes 
located in the F2RL3 gene, identified when comparing 
current and never smokers, in an attempt replicate the 
findings of Wan. Unfortunately, there were no 
participants that fell into both the fourth duration and 
fourth cessation quantiles and thus the average 
methylation could not be calculated for this group. 
However, for the other 15 groups there is a clear 
increase in DNA methylation with more years since 
quitting across all four duration quantile groups. The 
Figure	5.4.1.:	Relationship	between	duration	and	
cessation	on	DNA	methylation	at	three	loci.	Average	
DNA	methylation	for	each	of	the	16	groups,	split	
based	on	duration	and	cessation,	for	smoking-
associated	sites	located	in	F2RL3	(green,	top),	PRSS23	
(blue,	middle)	and	AHRR	(red,	bottom).	
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opposite is also true where DNA methylation is reduced with increasing years of smoking across all four 
cessation quantile groups. Therefore, average DNA methylation with increasing duration was greater for 
those who had the longest time since quitting and vice versa for increasing cessation.  This shows that 
participants who had smoked the longest and quit for the least number of years ago had the lowest average 
methylation at this F2RL3 locus. The same was also observed for the 8 smoking DMPs located on 
chromosome 11 in the PRSS23 gene and the top 10 DMPs located on chromosome 5 in the AHRR gene. 
The average methylation of the 16 groups at these three loci are displayed in Figure 5.4.1. Average DNA 
methylation had more variation for the PRSS23 and AHRR loci and thus the trend seen observed in F2RL3 
was not as clear. This may be caused by the small sample sizes within each group or perhaps different 
directional changes in DNA methylation on probes located in the same gene. Regardless, the obvious 
relationship between duration and cessation seen in the DNA methylation averages og the F2RL3 locus 
show that this gene is highly sensitive to both dosage and decay. It also hints at an interaction whereby the 
effect of one variable on DNA methylation is different at different values of other variables. Therefore, it 
is important to bear this in mind when creating a biomarker of cessation as this finding suggests that the 
rate and degree of DNA methylation change decay following smoking cessation is dependent on the years 
the individual had spent smoking before quitting, at least for some sites. This also strengthens the view that 
the reversal of methylome changes is more effective in those who have smoked for fewer years and, given 
the genes impacted by smoking, also argues that the best health outcomes can be proposed for those who 
quit as soon as possible after smoking initiation, regardless of the intensity of smoking during those years 
of tobacco use.  
 
5.5. Predicting Years Since Quitting 
 
A clear link between DNA methylation levels and smoking cessation has been established in this chapter. 
This offers an opportunity to use this quantification of DNA methylation in the creation of another predictor 
but this time for years since smoking cessation. This was carried out using the same protocol that Horvath 
developed when producing his epigenetic clock of age (Horvath, 2013) and as detailed in the previous 
chapter when predicting smoking duration.  
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The penalized regression model, with elastic net regularization, consisted of regressing a transformed 
version of cessation years from the training set, a sample of 178 former smokers, onto the 192 EPIC array 
probes associated with cessation. The elastic net predictor then automatically selects the CpG sites most 
associated with cessation and these were then used in the prediction. Before carrying out the regression, the 
cessation data was transformed by taking the cube root of each value. This altered the distribution shape of 
the data to make it perform better when carrying out the regression and also corrected for the slight right 
skewness of the data. The regression model was then run using the glmnet package from R as before 
(Friedman et al., 2010). Here the alpha parameter was again set to 0.5 and the lambda value set to 
0.03116628 as elucidated in a 10 fold cross validation using the same training set. The prediction of 
cessation was carried out using a test set consisting of the remaining former smokers and these values are 
compared to self-reported cessation lengths in Figure 5.5.1. 
 
This shows a correlation of 0.69 between the predicted and actual years since cessation, with a mean 
difference between the two of just 0.71 and a large standard deviation of 11.85. This large variation may 
Figure	5.5.1.:	Goodness	of	fit	for	predictor	of	years	since	quitting	smoking.	Shows	actual	years	
since	quitting	(x-axis)	against	predicted	years	since	quitting	(y-xis).	Pearson	correlation	coefficient	
=	0.69.	
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be explained by the varying duration these former smokers had spent smoking as it was observed that this 
can have an impact of the rate of DNA methylation change decay. It may also be the case that the reversal 
of DNA methylation is a multifaceted process and is more complicated than the accumulation of DNA 
methylation changes seen with increasing duration in current smokers. This might also explain the stronger 
correlation seen between predicted and actual years spent smoking despite the smaller sample size of 
current smokers available when creating it. Another limitation of the model comes from the lack of 
participants with a cessation period over 36 years. This may also explain why the model generally fits better 
in those with less than 36 years since quitting. With this said, the cessation predictor is still able to 
distinguish between those quitting for shorter or longer periods of time and this aspect may be beneficial 
as a biomarker of cessation. Furthermore, given the plethora of disease-related loci associated with 
smoking, such a biomarker may also give some indication of health outcomes for former smokers and 
relative risk of disease and cancer.  
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6. Summary 
 
This dissertation set out to consider the impact of smoking on DNA methylation in almost 1200 participants 
of the Understanding Society household study. Firstly, a simply qualitative comparison was made using 
linear models in the R package limma (Ritchie et al., 2015) which including the covariates of age, sex, 
blood process day, batch and estimates of blood leukocyte proportions (Houseman et al., 2012). This was 
run between beta methylation values, measured in whole blood using the Infinium MethylationEPIC 
BeadChip (Illumina, 2016) from participants with differing smoking statuses as reported in the wave 3 
questionnaires in the study. This revealed 5198 differentially methylated probes (DMPs) between current 
and never smokers, 826 between current and former smokers and 17 between former and never smokers 
after FDR adjustment for multiple testing. The majority of these loci were hypomethylated in smokers and 
ex-smokers compared to non-smokers and for the sites seen in all models, a reduction in their significance 
value and effect size was observed in each comparison. Within these DMPs came some novel probes 
located in genes whose DNA methylation state had not yet been linked to smoking. This included GNMT, 
related to the methyl donor for most cellular methylation reactions (Yen et al., 2013), and SLAMF7, a self-
ligand receptor in the signalling lymphocytic activation molecule family that is important in immunity (Guo 
et al., 2015). What this analysis could not show is any smoking-related variation in DNA methylation within 
active smoker and ex-smoker participants. To overcome this, a second set of analyses used quantitative 
data that detailed information on dosage, including the years spent smoking and the mean number of 
cigarettes smoked per day by participants. This was limited to participants who currently smoke given the 
reversal of DNA methylation changes observed in the qualitative analysis which may have hindered the 
linear models. Here a strong correlation between age and smoking duration became apparent and thus had 
to be removed from the model which then showed 1331 DMPs associated with years spent smoking. The 
intensity measure only yielded 23 DMPs. Additionally, effect sizes rose with increasing measures of both 
dosages however this was more strongly influenced by duration. Taken together this suggested that years 
of smoking is more closely linked to DNA methylation changes than number of cigarettes smoked. It also 
hints that duration rather than intensity is important in smoking-related disease as several genes associated 
with years spent smoking are crucial for good health. This suggested that DNA methylation levels might 
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offer potential as a biomarker for smoking years. Such a predictor was then created using a similar penalized 
regression approach, with elastic net regularization, to Horvath in his epigenetic clock of age. This was 
carried out in the glmnet R package (Friedman et al., 2010) where the predicted lengths of duration had a 
good correlation of 0.76 with the actual years spent smoking. The third and final analysis considered 
cessation and how it is involved in the decay of differential methylation between current and former 
smokers when compared to never smokers. A linear model yielded 192 DMPs associated with years since 
quitting in former smokers, most of which were hypermethylated. Looking at effect sizes, this 
hypermethylation of probes increased with increasing cessation, at least up to 36 years. The degree of 
reversed differential methylation was then quantified for each participant who had previously smoked by 
creating a smoking index (SI) using an equation created by Teschendorff et al. (2015). This measured the 
deviation of DNA methylation of the top 10 cessation-related probes from a non-smoker reference sample. 
In general, this showed that former smokers with the longest years since quitting had SI scores closer to 
zero than those with shorter cessation periods. As DNA methylation was clearly shown here to reflect the 
length of cessation of the participant, another predictor was created, using the same procedure as before, 
but this time for years since quitting. This showed a slightly weaker correlation of 0.69 between predicted 
and actual values for cessation but was still able to distinguish between long-term and short-term ex-
smokers. 
 
The work outlined in this dissertation has not only considered but perhaps advanced understandings of the 
relationship between DNA methylation and smoking. This has been done by identifying novel associations 
between DNA methylation at many CpG sites and tobacco use and further still through the creation of 
predictors capable of estimating years of duration in current smokers and years of cessation in former 
smokers. Thus, the aims of this project were met and has reinforced previous findings in this field of study. 
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